REVISION NOTES IN PSYCHIATRY

THIRD EDITION







BASANT K. PURI
ANNIE HALL
ROGER HO

CRC Press
Taylor & Francis Group

REVISION NOTES IN PSYCHIATRY

THIRD EDITION

REVISION NOTES IN PSYCHIATRY

THIRD EDITION

BASANT K. PURI
ANNIE HALL
ROGER HO

CRC Press
Taylor & Francis Group
Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

The authors acknowledge the following illustrators: Ms. Ja'naed Woods (for Chapter 1, "Descriptive Psychopathology"); Mr. Edwin Ng (for Chapter 7, "Cognitive Assessment and Neuropsychological Processes"); and Miss Anna Chua (for all other chapters).

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

Version Date: 20130916

International Standard Book Number-13: 978-1-4441-7014-6 (eBook - PDF)

Contents

Preface lxxvii
Authors lxxix
Abbreviations lxxxi

Chapter 1 Descriptive Psychopathology 1

1.1 Disorders of General Behaviour 1
1.1.1 Underactivity 1
1.1.1.1 Stupor 1
1.1.1.2 Depressive Retardation 1
1.1.1.3 Obsessional Slowness 1
1.1.2 Overactivity 1
1.1.2.1 Psychomotor Agitation 1
1.1.2.2 Hyperkinesis 1
1.1.2.3 Somnambulism (Sleep Walking) 1
1.1.2.4 Compulsion (Compulsive Ritual) 1
1.1.2.5 Abnormal Posture and Movements 1
1.2 Disorders of Speech 3
1.2.1 Disorders of Rate, Quantity, and Articulation 3
1.2.2 Disorders of the Form of Speech 3
1.2.3 Disorders (Loosening) of Association (Formal Thought Disorder) 4
1.3 Disorders of Emotion 4
1.3.1 Disorders of Affect 4
1.3.2 Disorders of Mood 4
1.3.3 Disorders Related to Anxiety 5
1.4 Disorders of Thought Content 5
1.4.1 Preoccupations 5
1.4.2 Obsessions 5
1.4.3 Phobias 5
1.5 Abnormal Beliefs and Interpretations of Events 6
1.5.1 Overvalued Ideas 6
1.5.2 Delusions 6
1.5.3 Passivity Phenomenon 6
1.5.4 Delusional Perception 7
1.6 Abnormal Experiences 7
1.6.1 Sensory Distortions 7
1.6.2 Sensory Deceptions 7
1.6.2.1 Illusions 7
1.6.2.2 Hallucinations 7
1.6.2.3 Pseudohallucinations (Coined by Kandinsky in 1885) 8
1.7 Disorders of Self-Awareness (Ego Disorders) 9
1.8 Cognitive Disorders 9
1.8.1 Disorientation 9
1.8.2 Disorders of Attention 9
1.8.3 Disorders of Memory 9
1.8.4 Disorders of Intelligence 10

1.8.5 Disorders of Consciousness 10
1.8.5.1 Levels of Consciousness 10
1.8.5.2 Clouding of Consciousness 10
1.8.5.3 Delirium 10
1.8.5.4 Fugue 10
1.8.5.5 Aphasias 10
1.9 Dyslexia 10
1.10 Agraphia 11
1.11 Alexia 11
1.12 Acalculia 11
1.13 Apraxias and Agnosias 11
1.13.1 Apraxias 11
1.13.2 Agnosias and Disorders of Body Image 12
Bibliography 15

Chapter 2 Classification 17

2.1 History of Classification Schemes 17
2.1.1 Ancient Greeks 17
2.1.2 Ancient Romans 17
2.1.3 Cullen 17
2.2 ICD 17
2.3 DSM 17
2.4 ICD-10 18
2.4.1 Organic, Including Symptomatic, Mental Disorders 18
2.4.2 Schizophrenia, Schizotypal, and Delusional Disorders 18
2.4.3 Mood (Affective) Disorders 18
2.4.4 Neurotic, Stress-Related, and Somatoform Disorders 18
2.4.5 Behavioural Syndromes Associated with Physiological Disturbances and Physical Factors 18
2.4.6 Disorders of Adult Personality and Behaviour 19
2.4.7 Mental Retardation 19
2.4.8 Disorders of Psychological Development 19
2.4.9 Behavioural and Emotional Disorders with Onset Usually Occurring in Childhood and Adolescence 19
2.5 DSM-IV-TR and DSM-5 19
2.5.1 Axis I: Clinical Disorders; Other Conditions That May Be a Focus of Clinical Attention 19
2.5.1.1 DSM-IV-TR and DSM-5: Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence (Excluding Mental Retardation Which Is Diagnosed on Axis II) 19
2.5.1.2 DSM-IV-TR and DSM-5: Delirium, Dementia, and Amnestic and Other Cognitive Disorders 20
2.5.1.3 DSM-IV-TR and DSM-5: Substance-Related Disorders 20
2.5.1.4 DSM-IV-TR and DSM-5: Schizophrenia and Other Psychotic Disorders 21
2.5.1.5 DSM-IV-TR and DSM-5: Depressive Disorders 22
2.5.1.6 DSM-IV-TR and DSM-5: Bipolar Disorders 22
2.5.1.7 DSM-IV-TR and DSM-5: Anxiety Disorders 22
2.5.1.8 DSM-IV-TR and DSM-5: Somatoform Disorders 22
2.5.1.9 DSM-IV-TR and DSM-5: Factitious Disorders 22
2.5.1.10 DSM-IV-TR and DSM-5: Sexual and Gender Identity Disorders 22

2.5.1.11 DSM-IV-TR and DSM-5: Eating Disorders....23
2.5.1.12 DSM-IV-TR and DSM-5: Sleep Disorders....23
2.5.1.13 DSM-IV-TR and DSM-5: Impulse-Control Disorders not Elsewhere Classified....23
2.5.1.14 Adjustment Disorders....23
2.5.2 AXIS II: Personality Disorders; Mental Retardation....23
2.5.2.1 Personality Disorders....23
2.5.2.2 Mental Retardation....24
2.5.3 Axis III: General Medical Conditions....24
2.5.4 Axis IV: Psychosocial and Environmental Problems....24
2.5.5 Axis V: Global Assessment of Functioning....24
Bibliography....24

Chapter 3 Basic Psychology....25

3.1 Principles of Learning Theory....25
3.1.1 Definition of Learning....25
3.1.2 Classical Conditioning....25
3.1.2.1 Definition and Introduction....25
3.1.2.2 Acquisition Stage....25
3.1.2.3 Delayed Conditioning....25
3.1.2.4 Simultaneous Conditioning....25
3.1.2.5 Trace Conditioning....25
3.1.2.6 Backward Conditioning....25
3.1.2.7 Higher-Order Conditioning....25
3.1.2.8 Extinction....25
3.1.2.9 Generalization....26
3.1.2.10 Discrimination....26
3.1.2.11 Incubation....26
3.1.2.12 Stimulus Preparedness....26
3.1.2.13 Little Albert....26
3.1.3 Operant Conditioning (Instrumental Learning)....26
3.1.3.1 Definition and Introduction....26
3.1.3.2 Trial-and-Error Learning/Behaviour....26
3.1.3.3 Law of Effect....26
3.1.3.4 Skinner Box....26
3.1.4 Observational Learning (Vicarious Learning/Modelling)....26
3.1.4.1 Definition and Introduction....26
3.1.4.2 Bobo Doll Experiments....27
3.1.4.3 Optimal Conditions for Observational Learning....27
3.1.4.4 Steps Involved in the Modelling Process....27
3.1.5 Cognitive Learning....27
3.1.5.1 Definition....27
3.1.5.2 Mechanisms....27
3.1.5.3 Assimilation Theory....27
3.1.6 Concepts of Extinction and Reinforcement in Explaining Behaviour....28
3.1.6.1 Extinction....28
3.1.6.2 Reinforcement....28
3.1.6.3 Punishment....28
3.1.6.4 Primary Reinforcement....28

3.1.6.5 Secondary Reinforcement 28
3.1.6.6 Schedules of Reinforcement 28
3.1.6.7 Motivation 28
3.1.7 Clinical Applications of Behavioural Treatments 28
3.1.7.1 Reciprocal Inhibition 28
3.1.7.2 Habituation 28
3.1.7.3 Chaining 29
3.1.7.4 Shaping 29
3.1.7.5 Cueing 29
3.1.7.6 Escape Conditioning 30
3.1.7.7 Avoidance Conditioning 30
3.1.7.8 Self-Control Therapy 30
3.1.7.9 Modelling Therapy 31
3.2 Phenomena of Visual and Auditory Perception 31
3.2.1 Perception 31
3.2.1.1 Definition 31
3.2.1.2 Absolute Threshold 31
3.2.1.3 Difference Threshold 31
3.2.1.4 Weber's Law 31
3.2.1.5 Fechner's Law 31
3.2.1.6 Signal Detection Theory 31
3.2.2 Perceptual Organization 31
3.2.2.1 Figure-Ground Differentiation 31
3.2.2.2 Object Constancy 32
3.2.2.3 Depth Perception 32
3.2.2.4 Perceptual Set 32
3.2.3 Relevance of Visual Perceptual Theory to Psychopathology 32
3.2.3.1 Illusions 32
3.2.3.2 Hallucinations 33
3.2.3.3 Other Psychopathologies 33
3.2.4 Development of Visual Perception 33
3.2.5 Culturally Sanctioned Distress States 33
3.2.5.1 Nocturnal Hallucinations in Ultra-Orthodox Jewish Israeli Men 33
3.2.5.2 Isolated Sleep Paralysis with Visual Hallucinations among Nigerian Students 34
3.2.5.3 Mu-Ghayeb 34
3.2.5.4 Auditory and Visual Hallucinations Related to Bereavement in the Caribbean 34
3.3 Information Processing and Attention 34
3.3.1 Information Processing 34
3.3.1.1 Data-Driven Processing 35
3.3.1.2 Conceptually Driven Processing 35
3.3.2 Attention 35
3.4 Factors Affecting Memory 35
3.4.1 Memory 35
3.4.1.1 Encoding/Registration 35
3.4.1.2 Storage 35
3.4.1.3 Retrieval 35
3.4.2 Influences upon Memory 36
3.4.3 Optimal Conditions for Encoding, Storage, and Retrieval of Information 36
3.4.3.1 Encoding/Registration 36
3.4.3.2 Storage 37

3.4.3.3 Retrieval....37
3.4.4 Memory Information Processing....37
3.4.4.1 Primary Working Memory Storage Capacity....37
3.4.4.2 Principle of Chunking....39
3.4.4.3 Semantic Memory....39
3.4.4.4 Episodic Memory....39
3.4.4.5 Skills Memory....39
3.4.4.6 Other Aspects of Long-Term/Secondary Memory....39
3.4.5 Process of Forgetting and the Influence of Emotional Factors on Retrieval....39
3.4.5.1 Forgetting....39
3.4.5.2 Theories of Forgetting....39
3.4.5.3 Influence of Emotional Factors on Retrieval....40
3.4.6 Processes of Interference, Schemata, and Elaboration....40
3.4.6.1 Interference....40
3.4.6.2 Schemata....40
3.4.6.3 Elaboration....40
3.5 Factors Affecting Thought....40
3.5.1 Relationship of Thought to Language....40
3.5.1.1 Concepts....40
3.5.1.2 Prototypes....41
3.5.2 Reasoning....41
3.5.2.1 Deductive Reasoning....41
3.5.2.2 Inductive Reasoning....42
3.5.3 Problem-Solving Strategies....43
3.5.3.1 Alternative Representations....43
3.5.3.2 Expertise....43
3.5.3.3 Computer Simulation....43
3.5.4 Algorithms....43
3.5.5 Heuristics....43
3.6 Factors Affecting Personality....44
3.6.1 Derivation of Nomothetic and Idiographic Theories....44
3.6.2 Trait and State Approaches....44
3.6.3 Construct Theory....46
3.6.4 Humanist Approaches....46
3.6.4.1 Roger's Self Theory....47
3.6.4.2 Maslow....47
3.6.5 Psychoanalytic Approaches....47
3.6.5.1 Freud's Stages of Psychosexual Development....47
3.6.5.2 Erikson's Stages of Development....48
3.6.6 Situationist Approach....48
3.6.7 Interactionist Approach....48
3.6.8 Inventories....48
3.6.8.1 16PF....48
3.6.8.2 MMPI....48
3.6.8.3 CPI....49
3.6.8.4 Other Inventories....50
3.6.8.5 Limitations....50
3.6.9 Rating Scales....50
3.6.9.1 SAP....50
3.6.9.2 SCID II....50
3.6.9.3 SIDP....50

3.6.9.4 PAS 50
3.6.9.5 PDE 51
3.6.9.6 IPDE 51
3.6.10 Repertory Grid 51
3.6.11 Q-Sort Schedule 51
3.7 Factors Affecting Motivation 51
3.7.1 Extrinsic Theories and Homeostasis 51
3.7.2 Hypothalamic Systems and Satiety 51
3.7.3 Intrinsic Theories 51
3.7.3.1 Optimal Arousal 51
3.7.3.2 Cognitive Dissonance 51
3.7.3.3 Attitude-Discrepant Behaviour 52
3.7.3.4 Need for Achievement 52
3.7.4 Curiosity Drive 52
3.7.5 Maslow's Hierarchy of Needs 52
3.8 Factors Affecting Emotion 52
3.8.1 Types of Emotion 52
3.8.2 Components of Emotional Response 52
3.8.3 James–Lange Theory 52
3.8.4 Cannon–Bard Theory 53
3.8.5 Schachter's Cognitive Labelling Theory and Cognitive Appraisal 53
3.9 Stress 53
3.9.1 Physiological and Psychological Aspects 53
3.9.2 Situational Factors 53
3.9.2.1 Life Events 53
3.9.3 Vulnerability and Invulnerability 53
3.9.4 Coping Mechanisms 53
3.9.5 Learned Helplessness 53
3.9.6 Locus of Control 54
References 54

Chapter 4 Social Psychology 57

4.1 Attitudes and How They Are Affected 57
4.1.1 Definition 57
4.1.2 Components 57
4.1.3 Measurement 57
4.1.3.1 Thurstone Scale 57
4.1.3.2 Likert Scale 57
4.1.3.3 Semantic Differential Scale 57
4.1.4 Attitude Change 57
4.1.5 Persuasive Communication 57
4.1.5.1 Communicator 57
4.1.5.2 Recipient 58
4.1.5.3 Message 58
4.1.6 Cognitive Consistency and Dissonance 58
4.2 Self-Psychology 58
4.2.1 Self-Concept 58
4.2.1.1 Self-Esteem 58
4.2.1.2 Self-Image 58

4.2.2 Self-Perception Theory 58
4.3 Interpersonal Issues 58
4.3.1 Interpersonal Attraction 58
4.3.2 Attribution Theory (Heider) 59
4.3.2.1 Internal or Dispositional Attribution 59
4.3.2.2 External or Situational Attribution 59
4.3.2.3 Primary (Fundamental) Attribution Error 59
4.3.3 Theory of Mind 59
4.4 Leadership, Social Influence, Power, and Obedience 59
4.4.1 Leadership 59
4.4.2 Social Facilitation 59
4.4.3 Social Power 59
4.4.4 Conformity 59
4.4.5 Obedience to Authority 60
4.5 Phenomenon of Aggression 60
4.5.1 Explanations 60
4.5.1.1 Psychoanalytic 60
4.5.1.2 Social Learning Theory 60
4.5.1.3 Operant Conditioning 60
4.5.1.4 Ethology 60
4.5.1.5 Frustration–Aggression Hypothesis 60
4.5.1.6 Arousal 60
4.5.2 Influence of Television 60
4.6 Concept of Altruism 60
Bibliography 61

Chapter 5 Human Growth and Development 63

5.1 Conceptualizing Development 63
5.1.1 Basic Concepts 63
5.1.2 Gene–Environment Interactions 63
5.1.3 Historical Models 63
5.2 Attachment and Bonding 63
5.2.1 Attachment Theory 63
5.2.2 Attachment Abnormalities 64
5.2.2.1 Insecure Attachment 64
5.2.2.2 Avoidant Attachment 64
5.2.3 Separation Anxiety 64
5.2.4 Acute Separation Reaction 64
5.2.5 Stranger Anxiety 64
5.2.6 Maternal Deprivation 64
5.3 Family Relationships and Parenting Practise 64
5.3.1 Child-Rearing Practise 64
5.3.2 Family Structure 65
5.3.3 Ordinal Position in Family 65
5.3.4 Distorted Family Function 65
5.3.5 Impact of Bereavement 65
5.3.6 Impact of Parental Divorce 65
5.3.7 Impact of Intrafamilial Abuse 65
5.3.7.1 Sexual Abuse 65

5.3.7.2 Physical Abuse/Nonaccidental Injury 66
5.4 Temperament 66
5.4.1 Individual Temperamental Differences 66
5.4.2 Origins, Typologies, and Stability of Temperament 67
5.5 Piaget's Model of Cognitive Development 68
5.5.1 Sensorimotor Stage 68
5.5.2 Preoperational Stage 68
5.5.3 Concrete Operational Stage 68
5.5.4 Formal Operational Stage 68
5.6 Language Development 69
5.6.1 Normal Childhood Development 69
5.6.2 Environmental Influences and Communicative Competence 69
5.7 Moral Development 69
5.7.1 Kohlberg's Stage Theory 69
5.7.1.1 Preconventional Morality (Level I) 69
5.7.1.2 Conventional Morality (Level II) 69
5.7.1.3 Postconventional Morality (Level III) 69
5.7.2 Relationship to the Development of Social Perspective Taking 70
5.8 Development of Fears in Childhood and Adolescence 70
5.8.1 Definition 70
5.8.2 Development with Age 70
5.8.3 Possible Etiological and Maintenance Mechanisms 70
5.8.3.1 Unconscious Conflict 70
5.8.3.2 Learned Response 70
5.8.3.3 Lack of Control 70
5.9 Sexual Development 70
5.9.1 Sex Determination 70
5.9.2 Changes at Puberty 71
5.9.2.1 Physical Changes 71
5.9.2.2 Onset in Girls 71
5.9.2.3 Onset in Boys 71
5.9.2.4 Physiological Changes 71
5.9.3 Gender Identity 71
5.9.4 Gender/Sex Typing 71
5.9.5 Gender Role 71
5.9.6 Sexual Behaviour 71
5.9.6.1 Sexual Drive 71
5.9.6.2 Childhood Sexuality 72
5.9.6.3 Masturbation 72
5.9.7 Sexual Orientation 72
5.9.7.1 Homosexuality 72
5.9.7.2 Modern Arguments in Favor of Biological Determinism 73
5.9.7.3 Arguments against Biological Determinism 74
5.10 Adolescence 74
5.10.1 Conflict with Parents and Authority 74
5.10.1.1 Cognitive Developmental Models 74
5.10.1.2 Erikson's Stages of Psychosocial Development 74
5.10.1.3 Ethological and Sociobiological Models 74
5.10.1.4 Social-Learning Theory 74
5.10.1.5 Equity Theory 74

5.10.1.6 Separation–Individuation 75
5.10.2 Affective Stability and 'Turmoil' 75
5.10.2.1 Anna Freud 75
5.10.2.2 Erikson 75
5.10.2.3 Offer and Offer 75
5.10.3 Normal and Abnormal Adolescent Development 75
5.10.3.1 Offer and Offer 75
5.10.3.2 Block and Haan 75
5.11 Adaptations in Adult Life 76
5.11.1 Pairing 76
5.11.1.1 Homogamous Mate Selection 76
5.11.1.2 Reinforcement Theory 76
5.11.1.3 Social Exchange Theory 76
5.11.1.4 Equity Theory 76
5.11.1.5 Matching Hypothesis 76
5.11.1.6 Cultural Differences 76
5.11.1.7 Cross-Cultural Constancies 76
5.11.2 Parenting 76
5.11.3 Grief, Mourning, and Bereavement 76
5.11.3.1 Definitions 76
5.11.3.2 Normal Grief 77
5.11.3.3 Bereavement 77
5.11.3.4 Morbid Grief Reactions 77
5.11.3.5 Differentiating between Bereavement and a Depressive Episode 77
5.12 Normal Ageing 77
5.12.1 Physical Aspects 77
5.12.1.1 Health 77
5.12.1.2 Cerebral Changes 77
5.12.2 Social Aspects 78
5.12.2.1 Stereotyping 78
5.12.2.2 Empty Nest Syndrome 78
5.12.3 Ego Integrity versus Despair 78
5.12.3.1 Ego Integrity 78
5.12.3.2 Despair 78
5.12.4 Cognitive Aspects 78
5.13 Death and Dying 78
5.13.1 Definitions 78
5.13.1.1 Timely Death 78
5.13.1.2 Untimely Death 78
5.13.1.3 Unintended Death 78
5.13.1.4 Intended Death 79
5.13.1.5 Subintended Death 79
5.13.2 Impending Death 79
References 79

Chapter 6 Description and Measurement 83

6.1 Description 83
6.1.1 Types of Data 83
6.1.1.1 Qualitative 83

6.1.1.2 Quantitative....83
6.1.2 Scales of Measurement....83
6.1.3 Sampling Methods....83
6.1.3.1 Simple Random Sampling....83
6.1.3.2 Systematic Sampling....83
6.1.4 Frequency Distributions....83
6.1.4.1 Frequency Distribution....83
6.1.4.2 Frequency Table....83
6.1.4.3 Relative Frequency....83
6.1.4.4 Cumulative Frequency....83
6.1.4.5 Cumulative Frequency Table....83
6.1.4.6 Cumulative Relative Frequency....84
6.1.4.7 Cumulative Relative Frequency Table....84
6.1.5 Discrete Probability Distributions....84
6.1.5.1 Bernoulli Trial....84
6.1.5.2 Bernoulli Distribution....84
6.1.5.3 Binomial Distribution....84
6.1.5.4 Poisson Distribution....84
6.1.6 Continuous Probability Distributions....84
6.1.6.1 Normal Distribution....84
6.1.6.2 *t* Distribution....85
6.1.6.3 χ^2 Distribution....85
6.1.6.4 *F* Distribution....86
6.1.7 Summary Statistics: Measures of Location....86
6.1.7.1 Measures of Central Tendency....86
6.1.7.2 Quantiles....86
6.1.8 Summary Statistics: Measures of Dispersion....86
6.1.8.1 Range....86
6.1.8.2 Measures Relating to Quantiles....86
6.1.8.3 Standard Deviation....86
6.1.8.4 Variance....87
6.1.9 Graphs....87
6.1.9.1 Definition....87
6.1.9.2 Drawing Graphs....87
6.1.9.3 Linear Relationship....87
6.1.9.4 Power Law Relationship....87
6.1.9.5 Exponential Relationship....87
6.1.9.6 Other Relationships Involving Expressions....88
6.1.10 Outliers....88
6.1.10.1 Measures of Central Tendency....88
6.1.10.2 Measures of Dispersion....88
6.1.10.3 Correlation and Linear Regression....88
6.1.11 Stem-and-Leaf Plots....88
6.1.12 Boxplots (Box-and-Whisker Plots)....88
6.1.13 Scatter Plot (Scattergrams, Scatter Diagrams, or Dot Graphs)....89
6.2 Principles of Measurement....90
6.2.1 Interviews....90
6.2.2 Self-Predictions....90
6.2.3 Psychophysiological Techniques....90
6.2.4 Naturalistic Observations....90

6.2.5 Scaling 90
6.2.6 Norm Referencing 90
6.2.7 Criterion Referencing 90
6.3 Intelligence 90
6.3.1 Aptitude 90
6.3.2 Attainment 90
6.3.3 Components of Intelligence 90
6.3.4 Mental Age Scale 91
6.3.5 Intelligence Quotient 91
6.3.6 Wechsler Adult Intelligence Scale 91
6.3.7 Wechsler Intelligence Scale for Children: Revised 91
6.3.8 Wechsler Preschool and Primary Scale of Intelligence 91
6.3.9 Group Ability Tests 91
6.3.10 Nature–Nurture 92
6.3.11 Cultural Influences 92
6.4 Techniques Used in Neuropsychological Assessment 92
6.4.1 Comprehensive Test Batteries 92
6.4.1.1 Halstead–Reitan Battery 92
6.4.1.2 Luria–Nebraska Neuropsychological Battery 92
6.4.1.3 Repeatable Battery for the Assessment of Neuropsychological Status 93
6.4.2 Language Tests 93
6.4.2.1 Boston Diagnostic Aphasia Examination, 3rd Edition 93
6.4.2.2 Boston Naming Test 93
6.4.2.3 Graded Naming Test 94
6.4.2.4 Token Test 94
6.4.2.5 Speed and Capacity of Language Processing Test 94
6.4.3 Perception Tests 94
6.4.3.1 Bender–Gestalt Test/Bender Visual Motor Gestalt Test 94
6.4.3.2 Visual Object and Space Perception Battery 94
6.4.3.3 Behavioural Inattention Test 94
6.4.4 Memory Tests 94
6.4.4.1 Benton Visual Retention Test 94
6.4.4.2 Graham–Kendall Memory for Designs Test 94
6.4.4.3 Rey–Osterrieth Test 94
6.4.4.4 Paired Associate Learning Tests 95
6.4.4.5 Synonym Learning Test 95
6.4.4.6 Object Learning Test 95
6.4.4.7 Rey Auditory Verbal Learning Test 95
6.4.4.8 California Verbal Learning Test 95
6.4.4.9 Wechsler Memory Scale-IV 95
6.4.4.10 Rivermead Behavioural Memory Test 95
6.4.4.11 Adult Memory and Information Processing Battery 95
6.4.5 Intelligence Tests 96
6.4.5.1 WAIS and Similar Tests 96
6.4.5.2 National Adult Reading Test 96
6.4.5.3 Raven's Progressive Matrices 96
6.4.6 Executive Function (Frontal Lobe) Tests 96
6.4.6.1 Stroop 96
6.4.6.2 Verbal Fluency 96
6.4.6.3 Tower of London Test 96

6.4.6.4 Wisconsin Card Sort Test 96
6.4.6.5 Cognitive Estimates Test 97
6.4.6.6 Six Elements Test 97
6.4.6.7 Multiple Errands Task 97
6.4.6.8 Trail Making Test 97
6.4.7 Personality Tests 97
6.4.7.1 Objective Tests 97
6.4.7.2 Projective Tests 98
6.4.8 Dementia Tests and Related Tests 98
6.4.8.1 Mini-Mental State Examination 98
6.4.8.2 Cambridge Neuropsychological Test Automated Battery 98
6.4.8.3 Gresham Ward Questionnaire 98
6.4.8.4 Blessed's Dementia Scale 99
6.4.8.5 Information–Memory–Concentration Test 99
6.4.8.6 Geriatric Mental State Schedule 99
6.4.8.7 Cambridge Examination for Mental Disorders 99
6.4.8.8 Crichton Geriatric Behaviour Rating Scale 99
6.4.8.9 Clifton Assessment Schedule 99
6.4.8.10 Stockton Geriatric Rating Scale 99
6.4.8.11 Present Behavioural Examination 99
6.4.8.12 Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia 99
6.4.8.13 Sandoz Clinical Assessment 99
6.4.8.14 Vineland Social Maturity Scale 100
6.4.8.15 Performance Test of Activities of Daily Living 100
References 100

Chapter 7 Cognitive Assessment and Neuropsychological Processes 103

7.1 Memory 103
7.1.1 Sensory Memory 103
7.1.1.1 Short-Term Memory 103
7.1.1.2 Explicit Memory 103
7.1.1.3 Implicit Memory 103
7.2 Amnesia 103
7.3 Language 103
7.3.1 Cerebral Dominance 103
7.3.1.1 Speech and Language Areas 103
7.3.1.2 Pathways 105
7.3.2 Dysphasias 105
7.3.2.1 Receptive Dysphasia 105
7.3.2.2 Expressive Dysphasia 105
7.3.2.3 Conduction Dysphasia 105
7.3.2.4 Global Dysphasia 105
7.3.3 Mutism 105
7.4 Perception 105
7.4.1 Visual Perception 105
7.4.1.1 Other Agnosias 106
7.5 Dyslexia and Dysgraphia 107
7.5.1 Dyslexia 107
7.5.2 Dysgraphia 107

7.6 Alexia and Agraphia 107
7.6.1 Alexia without Agraphia 107
7.6.2 Alexia with Agraphia 108
7.7 Apraxias 108
7.7.1 Acalculia and Anarithmetria 108
7.8 Frontal Lobe Functions 109
7.8.1 Prefrontal Cortex 109
7.8.2 Frontal Eye Fields 109
7.8.3 Motor and Premotor Cortex 110
7.8.4 Broca's Area 110
7.8.5 Orbital Cortex 110
7.8.6 Frontal Lobe Lesions 110
7.8.7 Assessment of Temporal Lobe Functions 110
7.9 Left and Right Cerebral Hemispheres 110
Bibliography 114

Chapter 8 Social Sciences and Stigma 115

8.1 Descriptive Terms 115
8.1.1 Social Class 115
8.1.1.1 Determinants 115
8.1.1.2 Occupational Classification 115
8.1.2 Socioeconomic Status 115
8.1.3 Relevance to Psychiatric Disorder and Health-Care Delivery 115
8.1.3.1 Psychiatric Disorder 115
8.1.3.2 Relationship between Social Class and Psychiatric Disorder 115
8.1.3.3 Health-Care Delivery 116
8.1.3.4 Pathways to Psychiatric Care 116
8.1.4 Black Report on Socioeconomic Inequalities in Health 116
8.1.4.1 Explanations 116
8.1.4.2 Changes after 10 Years 116
8.2 Historical Sociological Theories 117
8.2.1 Weber 117
8.2.1.1 Bureaucracy 117
8.2.1.2 Rationalization 117
8.2.1.3 Religion 117
8.2.2 Marx 117
8.2.2.1 Communism 117
8.2.2.2 Crime 117
8.2.2.3 Religion 117
8.2.3 Durkheim 117
8.2.3.1 Anomie 118
8.2.3.2 Suicide 118
8.2.4 Foucault 118
8.2.4.1 Principles of Exclusion 118
8.2.4.2 Sexuality 118
8.2.5 Parsons 118
8.2.6 Goffman 118
8.2.7 Habermas 118
8.3 Social Roles of Doctors and Illness 119
8.3.1 Social Role 119

8.3.2 Social Role of Doctors 119
8.3.3 Sick Role 119
8.3.3.1 Rights (Privileges) 119
8.3.3.2 Obligations 119
8.3.4 Illness Behaviour 119
8.3.4.1 Stages 119
8.3.4.2 Determinants 119
8.4 Family Life in Relation to Major Mental Illness 120
8.4.1 Elements of Family Functioning 120
8.4.2 Schizophrenia 120
8.4.2.1 Schizophrenogenic Mother 120
8.4.2.2 Double Bind 120
8.4.2.3 Marital Skew and Marital Schism 120
8.4.2.4 Abnormal Family Communication 120
8.4.2.5 Expressed Emotion 121
8.4.3 Mood Disorders 121
8.4.3.1 Expressed Emotion 121
8.4.3.2 Vulnerability Factors 121
8.4.4 Problem Drinking and Alcohol Dependence 121
8.4.5 Learning Disability/Mental Retardation 121
8.5 Life Events 122
8.5.1 Definition 122
8.5.2 Life-Change Scale 122
8.5.3 Aetiology of Psychiatric Disorders 122
8.5.4 Difficulties in the Evaluation of Life Events 122
8.5.5 Clinical Significance 122
8.5.5.1 Depression 122
8.5.5.2 Schizophrenia 123
8.5.5.3 Anxiety 123
8.5.5.4 Mania 123
8.5.5.5 Parasuicide/Deliberate Self-Harm 123
8.5.5.6 Functional Disorders 123
8.6 Residential Institutions 123
8.6.1 Social Institutions 123
8.6.1.1 Definition 123
8.6.1.2 Examples 123
8.6.2 Total Institutions 123
8.6.2.1 Definition 123
8.6.2.2 Examples 123
8.6.3 Goffman 123
8.6.3.1 Reactions to the Mortification Process 124
8.6.4 Institutional Neurosis 124
8.6.5 Secondary Handicap 124
8.6.5.1 Primary Handicap 124
8.6.5.2 Secondary Handicap 124
8.6.6 Three Mental Hospitals Study 124
8.7 Ethnic Minorities, Adaptation, and Mental Health 124
8.7.1 Prevalence of Schizophrenia 124
8.7.2 Causes of Different Prevalence Rates 124
8.7.3 Depression and Anxiety 125

8.8 Professions 125
8.8.1 Characteristics of Professions 125
8.8.2 Professional Groups Involved in Patient Care 125
8.9 Intergroup Behaviour and Stigma 125
8.9.1 Stereotypes 125
8.9.2 Stigma 125
8.9.2.1 Definition 125
8.9.2.2 Example 125
8.9.2.3 Enacted Stigma 125
8.9.2.4 Felt Stigma 125
8.9.2.5 Development 125
8.9.3 Prejudice 125
8.9.3.1 Definition 125
8.9.3.2 Example 126
8.9.3.3 Discrimination 126
8.9.3.4 Causes 126
8.9.3.5 Reducing Prejudice 126
References 126

Chapter 9 Dynamic Psychopathology and Psychoanalytic Theories 129

9.1 Basic Principles of Dynamic Psychotherapy 129
9.2 Sigmund Freud (1856–1939) 129
9.2.1 Early Influences 129
9.2.2 Protopsychoanalytic Phase (1887 to c.1897) 129
9.2.2.1 Studies on Hysteria 129
9.2.2.2 Technical Development 129
9.2.2.3 Project for a Scientific Psychology 129
9.2.3 Topographical Model of the Mind 130
9.2.3.1 Unconscious 130
9.2.3.2 Preconscious 130
9.2.3.3 Conscious 130
9.2.3.4 Censorship 130
9.2.3.5 Primary Process 130
9.2.3.6 Secondary Process 131
9.2.3.7 Pleasure Principle 131
9.2.3.8 Reality Principle 131
9.2.4 Dreaming 131
9.2.4.1 Dream Composition 131
9.2.4.2 Dream Work 131
9.2.5 Structural Model of the Mind 131
9.2.5.1 Id 131
9.2.5.2 Ego 131
9.2.5.3 Superego 132
9.2.5.4 Relationship between the Id, Ego, and Superego 132
9.2.6 Resistance 132
9.2.7 Transference 132
9.2.8 Countertransference 132
9.2.9 Instinctual Drives 132

9.2.10 Psychosexual Development 133
9.2.10.1 Oral Phase 133
9.2.10.2 Anal Phase 133
9.2.10.3 Phallic Phase 133
9.2.10.4 Latency Stage 133
9.2.10.5 Genital Stage 133
9.3 Carl Jung (1875–1961) 133
9.3.1 Early Influences 133
9.3.2 Differences between Jungian and Freudian Theory 133
9.3.2.1 Libido Theory 133
9.3.2.2 Nature of the Unconscious 133
9.3.2.3 Causality 133
9.3.2.4 Dreaming 133
9.3.3 Archetypes 133
9.3.3.1 Anima 133
9.3.3.2 Animus 133
9.3.3.3 Persona 134
9.3.3.4 Shadow 134
9.3.3.5 Self 134
9.3.4 Complexes 134
9.3.5 Mental Operations 134
9.3.5.1 Feeling 134
9.3.5.2 Intuition 134
9.3.5.3 Sensation 134
9.3.5.4 Thinking 134
9.3.6 Extroversion and Introversion 134
9.3.6.1 Extroversion 134
9.3.6.2 Introversion 134
9.3.7 Individuation 134
9.4 Melanie Klein (1882–1960) 134
9.4.1 Background 134
9.4.2 Differences between Kleinian and Freudian Theory 134
9.4.2.1 Object Relations 134
9.4.2.2 Paranoid-Schizoid Position 134
9.4.2.3 Aggression 135
9.4.2.4 Depressive Position 135
9.4.2.5 Development of the Ego and Superego 135
9.4.3 Early Development 135
9.4.4 Analytic Play Technique 135
9.5 Donald Winnicott (1897–1971) 135
9.5.1 Background 135
9.5.2 Mother–Baby Dyad 135
9.5.3 Countertransference 135
9.5.3.1 Objective Countertransference 135
9.5.3.2 Countertransference Hate 135
9.5.4 Motherhood 135
9.5.4.1 Good-Enough Mother 135
9.5.4.2 Pathological Mother 135
9.5.4.3 Capacity to Be Alone 136
9.5.5 Transitional Object 136
9.5.6 Other Concepts 136

9.6 Psychodynamic Theory of Defence Mechanisms 136
9.6.1 Repression 136
9.6.2 Reaction Formation 136
9.6.3 Isolation 136
9.6.4 Undoing (What Has Been Done) 136
9.6.5 Projection 136
9.6.6 Projective Identification 136
9.6.7 Identification 136
9.6.8 Introjection 136
9.6.9 Incorporation 136
9.6.10 Turning against the Self 137
9.6.11 Reversal into the Opposite 137
9.6.12 Rationalization 137
9.6.13 Sublimation 137
9.6.14 Idealization 137
9.6.15 Regression 137
9.6.16 Denial 137
9.6.17 Splitting 137
9.6.18 Distortion 137
9.6.19 Acting Out 137
9.6.20 Displacement 137
9.6.21 Intellectualization 137
Bibliography 137

Chapter 10 History of Psychiatry 139

10.1 Before Common Era (BCE) 139
10.2 Common Era 139
10.3 Middle Ages 139
10.4 1247–1320 139
10.5 1700s 139
10.6 1790–1830 139
10.7 1830–1914 139
10.8 1830s 139
10.9 1840s 139
10.10 1850s 140
10.11 1860s 140
10.12 1870s 140
10.13 1880s and 1890s 140
10.14 1900s 140
10.15 1910s 141
10.16 1920s 141
10.17 1930s 141
10.18 1940s 142
10.18.1 Development of Psychotherapies in the 1940s 142
10.19 1950s 143
10.20 1960s 143
10.21 1970s 143
10.22 1980s 143
10.23 1990s 143

10.24 2000s 144
Bibliography 144

Chapter 11 Basic Ethics, Principles of Law, and Philosophy of Psychiatry 145

11.1 Ethical Standards and Codes of Practise 145
11.1.1 Hippocratic Oath 145
11.1.2 Declaration of Geneva (1948) 145
11.1.3 Declaration of Madrid 145
11.1.4 Royal College of Psychiatrists 145
11.2 Classical Ethical Theories 145
11.2.1 Utilitarian Theories 145
11.2.2 Deontological Theories (aka the Kantian Theories) 146
11.2.3 Virtue Theories (Plato and Aristotle) 146
11.2.3.1 Ethical Principles 146
11.2.3.2 Other Ethical Theories 146
11.2.3.3 Confidentiality and Privileges 146
11.2.3.4 Exceptions to Confidentiality 147
11.2.3.5 Approaches to Breach Confidentiality 147
11.2.3.6 Confidentiality in Minors 147
11.3 Ethics and Psychiatric Research 147
11.3.1 Nuremberg Code (1947) 147
11.3.2 Declaration of Helsinki (1964) 148
11.3.3 Belmont Report (1979) 148
11.4 Competency and Capacity 148
11.4.1 Competency 148
11.4.2 Capacity 148
11.4.2.1 Capacity for Informed Consent 148
11.5 Principles of Law 149
11.5.1 Mental Capacity Act (2005) (England and Wales) 149
11.5.1.1 Principles of the Mental Capacity Act (2005) 151
11.5.1.2 Three Parts of the Mental Capacity Act (2005) 151
11.5.2 Mental Health Act (MHA, 2007) in England and Wales 151
11.6 Philosophy of Psychiatry 154
11.6.1 Philosophy and Science 154
11.6.2 Formal and Informal Logic 154
11.6.3 Philosophy of Anti- and Propsychiatry 155
11.6.3.1 Philosophy of Antipsychiatry 155
Bibliography 158

Chapter 12 Neurology and Neurological Examination 159

12.1 Cranial Nerves (CNs II, III, IV, and VI) and the Visual System 159
12.1.1 Central Visual Pathway and Visual Field Deficits 159
12.1.1.1 Common Lesions in the Central Visual Pathway 159
12.2 Cranial Nerves (CNs III, IV, and VI) and Double Vision 159
12.2.1 Oculomotor Nerve (CN III) 159
12.2.2 Trochlear Nerve (CN IV) 160
12.2.3 Abducens Nerve (CN VI) 160

12.2.4 Medial Longitudinal Fasciculus 161
12.2.4.1 Examination of the Pupils and Related Conditions 161
12.2.5 Trigeminal Nerve (CN V) 162
12.2.6 Facial Nerve 163
12.2.7 Vestibulocochlear Nerve (CN VIII) 163
12.2.7.1 Weber's Test 163
12.2.7.2 Rinne's Test 164
12.2.7.3 Anatomy of the Auditory System 164
12.3 Other Cranial Nerves 165
12.3.1 Spinal Cord 165
12.3.1.1 Spinothalamic Tracts 166
12.3.1.2 Second-Order Neurons 166
12.3.1.3 Third-Order Neurons 166
12.3.2 Dorsal Column 166
12.3.2.1 Ascending Dorsal Columns 166
12.3.2.2 Decussation in the Medulla 167
12.3.2.3 Third-Order Neurons 167
12.3.4 Corticospinal and Corticobulbar Tracts 167
12.4 Myotomes and Neurological Examination in the CASC 168
12.4.1 Myotomes of the Upper Limb 168
12.4.2 Myotomes of the Lower Limb 169
12.5 Dermatomes 171
12.6 Compression and Entrapment Neuropathies 172
12.7 Other Neurological Conditions 172
12.7.1 Headache 172
12.7.1.1 Types of Headache 172
12.7.2 Pellagra 172
12.7.3 Blepharospasm 172
12.7.4 Other Dystonia 172
12.7.4.1 Gait Abnormalities 174
12.7.4.2 Ekbom's Syndrome (Restless Leg Syndrome) 174
12.7.4.3 Peripheral Neuropathies 174
12.7.4.4 Guillain–Barré Syndrome 174
Acknowledgments 174
Bibliography 174

Chapter 13 Neuroanatomy 175

13.1 Organization of the Nervous System 175
13.1.1 Structural Organization 175
13.1.1.1 Central Nervous System 175
13.1.1.2 Peripheral Nervous System 175
13.1.2 Functional Organization 175
13.1.2.1 Somatic Nervous System 175
13.1.2.2 Autonomic Nervous System 175
13.1.3 Developmental Organization 175
13.2 Types of Nervous System Cell 176
13.2.1 Neurons 176
13.2.1.1 Classification by Morphology 176
13.2.1.2 Classification by Size 176

13.2.2 Neuroglia 176
13.2.2.1 Relative Numbers 176
13.2.2.2 Central Nervous System 176
13.2.2.3 Peripheral Nervous System 176
13.2.2.4 Astrocytes 176
13.2.2.5 Oligodendrocytes 177
13.2.2.6 Microglia 177
13.2.2.7 Ependymal Cells 177
13.2.2.8 Schwann Cells 177
13.2.2.9 Satellite Cells 177
13.3 Frontal Lobes 177
13.3.1 Frontal Operculum 177
13.3.1.1 Broca's Area 177
13.3.1.2 Right Side 177
13.3.2 Superior Mesial Region 177
13.3.3 Inferior Mesial Region 177
13.3.3.1 Orbital Cortex 177
13.3.3.2 Basal Forebrain 177
13.3.4 Dorsolateral Prefrontal Cortex 177
13.4 Temporal Lobes 178
13.4.1 Superior Temporal Gyrus 178
13.4.2 Posterior Inferolateral Region 179
13.4.3 Anterior Inferolateral Region 179
13.4.4 Mesial Temporal Region 179
13.5 Parietal Lobes 179
13.5.1 Temporoparietal Junction 179
13.5.2 Inferior Parietal Lobule 180
13.6 Occipital Lobes 180
13.7 Basal Ganglia 180
13.7.1 Components 180
13.7.2 Connections of the Lentiform Nucleus 180
13.7.2.1 Afferents 180
13.7.2.2 Efferents 181
13.7.3 Frontal–Subcortical Circuits 181
13.7.3.1 Motor Circuit 181
13.7.3.2 Oculomotor Circuit 181
13.7.3.3 Dorsolateral Prefrontal Circuit 181
13.7.3.4 Lateral Orbitofrontal Circuit 181
13.7.3.5 Anterior Cingulate Circuit 181
13.8 Limbic System 181
13.8.1 Limbic Lobe 181
13.8.1.1 Cortical Areas 181
13.8.1.2 Nuclei 181
13.8.2 Components 181
13.8.2.1 Cortical Areas 181
13.8.2.2 Nuclei 182
13.8.2.3 Connecting Pathways 182
13.9 Internal Anatomy of the Temporal Lobes 182
13.9.1 Hippocampal Formation 182
13.9.1.1 Dentate Gyrus 182

13.9.1.2 Hippocampus ... 182
13.9.1.3 Parahippocampal Gyrus ... 182
13.9.2 Amygdala ... 182
13.9.2.1 Afferent Connections ... 182
13.9.2.2 Efferent Connections ... 183
13.10 Major White Matter Pathways ... 183
13.10.1 Corpus Callosum ... 183
13.10.1.1 Divisions ... 183
13.10.2 Fornix ... 183
13.10.2.1 Destination of Fibres in the Fornix ... 183
13.10.3 Papez Circuit ... 183
13.10.4 Arcuate Bundle ... 184
13.10.5 Anterior Commissure ... 184
13.11 Cranial Nerves ... 184
13.11.1 Olfactory Nerve ... 184
13.11.2 Optic Nerve ... 184
13.11.3 Oculomotor Nerve ... 184
13.11.4 Trochlear Nerve ... 184
13.11.5 Trigeminal Nerve ... 184
13.11.5.1 Nuclei ... 185
13.11.5.2 Sensory Components ... 185
13.11.5.3 Motor Component ... 185
13.11.6 Abducens Nerve ... 185
13.11.7 Facial Nerve ... 185
13.11.7.1 Nuclei ... 185
13.11.7.2 Main Motor Nucleus ... 185
13.11.7.3 Parasympathetic Nuclei ... 186
13.11.7.4 Sensory Nucleus ... 186
13.11.7.5 Chorda Tympani ... 186
13.11.8 Vestibulocochlear Nerve ... 186
13.11.8.1 Cochlear Nerve ... 186
13.11.8.2 Vestibular Nerve ... 186
13.11.9 Glossopharyngeal Nerve ... 186
13.11.9.1 Nuclei ... 186
13.11.9.2 Main Motor Nucleus ... 186
13.11.9.3 Parasympathetic Nucleus ... 186
13.11.9.4 Sensory Nucleus ... 186
13.11.10 Vagus Nerve ... 186
13.11.10.1 Nuclei ... 186
13.11.10.2 Main Motor Nucleus ... 186
13.11.10.3 Parasympathetic Nucleus ... 187
13.11.10.4 Sensory Nucleus ... 187
13.11.11 Accessory Nerve ... 187
13.11.11.1 Cranial Root ... 187
13.11.11.2 Spinal Root ... 187
13.11.12 Hypoglossal Nerve ... 187
13.12 Spinal Cord ... 187
13.12.1 Divisions ... 187
13.12.2 Ascending White Column Tracts ... 187
13.12.2.1 Anterior ... 188

13.12.2.2 Lateral 188
13.12.2.3 Posterior 188
13.12.3 Descending White Column Tracts 188
13.12.3.1 Anterior 189
13.12.3.2 Lateral 189
13.13 Major Neurochemical Pathways 189
13.13.1 Nigrostriatal Dopaminergic Pathway 189
13.13.2 Mesolimbic–Mesocortical Dopaminergic Pathway 190
13.13.3 Ascending Noradrenergic Pathway from the Locus Coeruleus 190
13.13.4 Basal Forebrain Cholinergic Pathway 191
13.13.5 Brain Stem Cholinergic Pathway 191
13.13.6 Glutamate System 193
13.13.7 Ascending Serotonin System 193
Bibliography 193

Chapter 14 Neuropathology 195

14.1 Dementias 195
14.1.1 Alzheimer's Disease 195
14.1.1.1 Macroscopic Neuropathology 195
14.1.1.2 Histopathology 195
14.1.1.3 Ultrastructural Pathology 195
14.1.1.4 Neurochemical Pathology 195
14.1.2 Pick's Disease 195
14.1.2.1 Macroscopic Neuropathology 195
14.1.2.2 Histopathology 195
14.1.2.3 Ultrastructural Pathology 196
14.1.3 Multi-Infarct Dementia 196
14.1.3.1 Macroscopic Neuropathology 196
14.1.3.2 Histopathology 196
14.1.4 Lewy Body Disease 196
14.1.4.1 Histopathology 196
14.1.4.2 Ultrastructural Pathology 196
14.1.5 Creutzfeldt–Jakob Disease 196
14.1.5.1 Macroscopic Neuropathology 196
14.1.5.2 Histopathology 196
14.1.6 Punch-Drunk Syndrome 197
14.1.6.1 Macroscopic Neuropathology 197
14.1.6.2 Histopathology 197
14.2 Cerebral Tumours 197
14.2.1 Types 197
14.2.2 Gliomas 197
14.2.3 Metastases 197
14.2.4 Meningeal Tumours 197
14.2.5 Pituitary Adenomas 197
14.2.6 Neurilemmomas 197
14.2.7 Haemangioblastomas 197
14.2.8 Medulloblastomas 197
14.3 Schizophrenia 198
14.3.1 Gross Neuropathology 198
14.3.1.1 Brain Mass 198

14.3.1.2 Brain Length 198
14.3.1.3 Cerebral Volumes 198
14.3.1.4 Hippocampus and Parahippocampal Gyrus 198
14.3.1.5 Ventricular Volume 198
14.3.1.6 Temporal Lobe 198
14.3.2 Morphometric Studies 198
14.3.2.1 Temporal Lobe 198
14.3.2.2 Other Cortical Areas 199
14.3.2.3 Other Brain Regions 199
14.3.3 Synaptic Pathology 199
14.3.3.1 Synaptic Vesicles 199
14.3.3.2 Synaptophysin 199
14.3.4 Gliosis 199
14.3.5 Antipsychotic Medication 199
14.4 Autism 200
14.4.1 Histological Changes 200
14.4.2 Cerebellar Pathology 200
14.4.2.1 Reduced Purkinje Cell Count 200
14.4.2.2 Neocerebellar Abnormality 200
14.5 Movement Disorders 200
14.5.1 Parkinson's Disease 200
14.5.1.1 Macroscopic Neuropathology 200
14.5.1.2 Histopathology 200
14.5.1.3 Neurochemical Pathology 201
14.5.2 Huntington's Disease (Chorea) 201
14.5.2.1 Macroscopic Neuropathology 201
14.5.2.2 Histopathology 201
14.5.2.3 Neurochemical Pathology 201
14.5.3 Tardive Dyskinesia 201
14.5.3.1 Dopamine Hypersensitivity Hypothesis 201
14.5.3.2 Free-Radical-Induced Neurotoxicity 202
14.5.3.3 GABA Insufficiency 202
14.5.3.4 Noradrenergic Dysfunction 203
References 203

Chapter 15 Neuroimaging Techniques 205

15.1 X-Ray 205
15.1.1 Basis 205
15.1.2 Type of Imaging 205
15.1.3 Neuropsychiatric Applications 205
15.2 CT 205
15.2.1 Basis 205
15.2.2 Type of Imaging 205
15.2.3 Neuropsychiatric Applications 205
15.3 PET 205
15.3.1 Basis 205
15.3.2 Type of Imaging 206
15.3.3 Neuropsychiatric Applications 206
15.4 SPECT 206
15.4.1 Basis 206

15.4.2 Type of Imaging 206
15.4.3 Neuropsychiatric Applications 206
15.5 MRI 206
15.5.1 Basis 206
15.5.2 Type of Imaging 208
15.5.3 Neuropsychiatric Applications 208
Bibliography 208

Chapter 16 Neurophysiology 209

16.1 Physiology of Neurons, Synapses, and Receptors 209
16.1.1 Neurons 209
16.1.1.1 Resting Membrane Ion Permeabilities 209
16.1.1.2 Resting Membrane Potential 209
16.1.1.3 Changes in Membrane Ion Permeabilities 209
16.1.1.4 Action Potential 209
16.1.1.5 Propagation of Action Potential 209
16.1.1.6 All-or-None Phenomenon 209
16.1.1.7 Absolute Refractory Period 209
16.1.1.8 Relative Refractory Period 209
16.1.1.9 Conduction in Unmyelinated Fibres 209
16.1.1.10 Conduction in Myelinated Fibres 209
16.1.2 Synapses 209
16.1.2.1 Synaptic Cleft 209
16.1.2.2 Location 209
16.1.2.3 Types 210
16.1.2.4 Synaptic Transmission 210
16.1.2.5 Excitatory Postsynaptic Potentials 210
16.1.2.6 Inhibitory Postsynaptic Potentials 210
16.1.2.7 Summation 210
16.1.3 Receptors 210
16.1.3.1 Sensory Receptors 210
16.1.3.2 Adaptation 210
16.2 Pituitary Hormones 211
16.2.1 Anterior Pituitary Hormones 211
16.2.1.1 ACTH 211
16.2.1.2 FSH 211
16.2.1.3 LH 211
16.2.1.4 MSH 212
16.2.1.5 Prolactin 212
16.2.1.6 GH 212
16.2.1.7 TSH 212
16.2.2 Posterior Pituitary Hormones 212
16.2.2.1 AVP or ADH 212
16.2.2.2 Oxytocin 212
16.3 Integrated Behaviours 212
16.3.1 Regulatory Behaviour 212
16.3.2 Pain 212
16.3.3 Motor Function 212
16.3.4 Arousal 213
16.3.5 Sexual Behaviour 213

16.3.6 Hunger 213
16.3.6.1 Insulin 213
16.3.6.2 Satiety Signals 214
16.3.6.3 Hypothalamus 214
16.3.6.4 Ghrelin 214
16.3.6.5 Cognitive Factors 214
16.3.7 Thirst 214
16.3.7.1 Osmotic Thirst 215
16.3.7.2 Hypovolaemic Thirst 215
16.4 Arousal and Sleep 216
16.4.1 Sleep Architecture 216
16.4.1.1 REM and NREM Sleep 216
16.4.1.2 Stages of Sleep 216
16.4.2 Physiological Correlates of Sleep 216
16.4.2.1 REM Sleep 216
16.4.2.2 NREM Sleep 216
16.4.3 Causes of the Sleeping–Waking Cycle 216
16.4.3.1 Monoaminergic Model 216
16.4.3.2 Cellular Model 216
16.5 EEG 217
16.5.1 Recording Techniques 217
16.5.1.1 Conventional 217
16.5.1.2 Specialized 217
16.5.2 Normal EEG Rhythms 217
16.5.2.1 Classification according to Frequency Band 217
16.5.2.2 Lambda Activity 217
16.5.2.3 Mu Activity 217
16.5.3 Spikes and Waves 217
16.5.3.1 Spikes 217
16.5.3.2 Sharp Waves 217
16.5.4 Effect of Drugs 217
16.5.4.1 Antidepressants 217
16.5.4.2 Antipsychotics 217
16.5.4.3 Anxiolytics 217
16.5.4.4 Lithium 217
Bibliography 217

Chapter 17 Neurochemistry 219

17.1 Transmitter Synthesis, Storage, and Release 219
17.1.1 Transmitter Synthesis 219
17.1.2 Transmitter Storage 219
17.1.3 Transmitter Release 219
17.2 Ion Channels 219
17.2.1 6-Transmembrane (TM) Family 219
17.2.2 2-TM Family 219
17.2.3 4-TM or 8-TM Family 219
17.2.4 Ionotropic Glutamate Receptors 219
17.2.5 Nicotinic ACh and Related Receptors 219
17.2.6 Intracellular Calcium Ion Channels 220
17.2.7 Chloride Ion Channels 220

17.3 Receptors 220
17.3.1 Structure 220
17.3.2 Function 220
17.3.2.1 G Proteins 220
17.3.2.2 Second Messengers 220
17.3.2.3 Acetylcholine 220
17.3.3 Cholinergic Receptors 221
17.3.3.1 Muscarinic Receptors 221
17.3.3.2 Nicotinic Receptors 222
17.3.3.3 Dopamine 222
17.3.3.4 Disease Processes Involving DA 223
17.3.3.5 Dopamine Receptors 224
17.3.3.6 Noradrenaline 224
17.3.3.7 NA and Psychiatric Disorders 226
17.3.4 Adrenoceptors 226
17.3.4.1 α-Adrenoceptors 226
17.3.4.2 β-Adrenoceptors 227
17.3.4.3 Serotonin (5-HT) 228
17.3.4.4 Serotonin and Psychiatric Disorders 228
17.3.5 Serotonergic Receptors 229
17.3.5.1 γ-Aminobutyric Acid (GABA) 229
17.3.5.2 GABA and Disease Processes 229
17.3.5.3 GABA Receptors 229
17.3.5.4 Glutamate 232
17.3.5.5 Clinical Relevance of Glutamate 232
17.3.6 Glutamate Receptors 232
17.3.6.1 NMDA Receptors 232
17.3.6.2 AMPA Receptors 232
17.3.6.3 KA Receptors 232
17.3.6.4 mGluRs 233
17.3.6.5 Neuropeptides 233
17.3.7 Endogenous Opioids 234
Acknowledgments 234
References 234

Chapter 18 General Principles of Psychopharmacology 237

18.1 Historical Overview 237
18.1.1 Antidepressants 237
18.1.1.1 Tricyclic Antidepressants and MAOIs 237
18.1.1.2 SSRIs 237
18.1.1.3 RIMA, SNRI, NARI, and NaSSA 237
18.1.2 Lithium 237
18.1.3 Antipsychotics 237
18.1.3.1 Reserpine 237
18.1.3.2 Typical Antipsychotics 237
18.1.3.3 Clozapine 237
18.1.4 Anxiolytics 238
18.1.4.1 Barbiturates 238
18.1.4.2 Benzodiazepines 238

18.2 Classification 238
18.2.1 Antipsychotics (Neuroleptics) 238
18.2.1.1 First-Generation (Typical) Antipsychotics 238
18.2.1.2 Second-Generation (Atypical) Antipsychotics 238
18.2.2 Antimuscarinics (Anticholinergics) 238
18.2.3 Prophylaxis of Bipolar Mood Disorder 238
18.2.4 Antidepressants 238
18.2.4.1 Tricyclic Antidepressants 238
18.2.4.2 Tricyclic-Related Antidepressants 238
18.2.4.3 Tetracyclic Antidepressants 238
18.2.4.4 MAOIs 239
18.2.4.5 SSRIs 239
18.2.4.6 RIMA 239
18.2.4.7 SNRI 239
18.2.4.8 NARI 239
18.2.4.9 NaSSA 239
18.2.4.10 Others 239
18.2.5 Nonbenzodiazepine Hypnotics 239
18.2.6 Benzodiazepines 239
18.2.7 Other Anxiolytics 239
18.2.8 Drugs Used in Alcohol Dependence 239
18.2.9 Drugs Used in Opioid Dependence 239
18.2.10 Antiandrogens 239
18.2.11 Drugs for Alzheimer's Disease 239
18.3 Optimizing Patient Compliance 240
18.4 Placebo Effect 240
18.4.1 Definition 240
18.4.2 Mechanisms of the Placebo Effect 240
18.4.3 Pill Factors 240
18.4.4 Controlling for the Placebo Effect 240
18.5 Prescribing for Psychiatric Patients 240
18.6 Pharmacokinetics 241
18.6.1 Absorption 241
18.6.1.1 Routes of Administration 241
18.6.1.2 Rate of Absorption 241
18.6.1.3 Oral Administration 241
18.6.1.4 Rectal Administration 241
18.6.1.5 Intramuscular Administration 241
18.6.1.6 Intravenous Administration 242
18.6.2 Distribution 242
18.6.2.1 Lipid Solubility 242
18.6.2.2 Plasma–Protein Binding 242
18.6.2.3 Volume of Distribution 242
18.6.2.4 Blood–Brain Barrier and Brain Distribution 243
18.6.2.5 Placenta 243
18.6.3 Metabolism 243
18.6.3.1 Hepatic Phase I Metabolism (Biotransformation) 243
18.6.3.2 Hepatic Phase II Metabolism (Biotransformation) 244
18.6.3.3 First-Pass Effect 244
18.6.4 Elimination 244

18.7 Pharmacodynamics 244
18.7.1 Antipsychotics 244
18.7.1.1 First-Generation Antipsychotics 244
18.7.1.2 Second-Generation Antipsychotics 245
18.7.2 Drugs Used in the Treatment of Mood Disorder 245
18.7.2.1 Lithium 245
18.7.2.2 Tricyclic Antidepressants 245
18.7.2.3 SSRIs 245
18.7.2.4 MAOIs 245
18.7.2.5 RIMA 246
18.7.2.6 SNRI 246
18.7.2.7 NARI 246
18.7.2.8 NaSSA 246
18.7.2.9 Asenapine 246
18.7.2.10 Agomelatine 246
18.7.3 Anxiolytics and Hypnotics 246
18.7.3.1 Benzodiazepines 246
18.7.3.2 Buspirone 246
18.7.3.3 β-Adrenoceptor Blocking Drugs 246
18.7.3.4 Zopiclone 247
18.7.3.5 Zolpidem 247
18.7.3.6 Zaleplon 247
18.7.4 Drugs for Alzheimer's Disease 247
18.7.5 Antiepileptic Agents 247
18.7.5.1 Carbamazepine 247
18.7.5.2 Sodium Valproate 247
18.7.5.3 Phenytoin 247
18.7.5.4 Phenobarbitone 247
18.7.5.5 Gabapentin 247
18.7.5.6 Vigabatrin 247
18.7.5.7 Lamotrigine 247
18.7.5.8 Levetiracetam 247
18.7.5.9 Lacosamide 247
18.7.6 Neurochemical Effects of ECT 248
18.7.6.1 Noradrenaline 248
18.7.6.2 Serotonin 248
18.7.6.3 Dopamine 248
18.7.6.4 GABA 248
18.7.6.5 Acetylcholine 248
18.7.6.6 Endogenous Opioids 248
18.7.6.7 Adenosine 248
Bibliography 248

Chapter 19 Psychotropic Drugs and Adverse Drug Reactions 251

19.1 Do Psychotropic Drugs Work? 251
19.1.1 CATIE and CUtLASS 251
19.1.1.1 CATIE 251
19.1.1.2 CUtLASS 251
19.2 Types of Adverse Drug Reactions 251
19.2.1 Classification 251

19.2.2 Causal Relationship 251
19.2.3 Intolerance 252
19.2.4 Idiosyncratic Reactions 252
19.2.5 Allergic Reactions 252
19.2.6 Drug Interactions 252
19.2.6.1 Pharmacokinetic Interactions 252
19.2.6.2 Pharmacodynamic Interactions 252
19.3 Psychotropic Medication 252
19.3.1 First-Generation Antipsychotics 252
19.3.1.1 Photosensitization 252
19.3.1.2 Hypothermia or Pyrexia 252
19.3.1.3 Allergic (Sensitivity) Reactions 253
19.3.1.4 Neuroleptic Malignant Syndrome 253
19.3.1.5 Chronic Pharmacotherapy 253
19.3.2 Second-Generation Antipsychotics 253
19.3.2.1 Clozapine 253
19.3.2.2 General Side Effects 253
19.3.3 Antimuscarinic Drugs 253
19.3.4 Lithium 253
19.3.4.1 Renal Function 253
19.3.4.2 Plasma Levels 253
19.3.4.3 Side Effects 253
19.3.4.4 Intoxication 254
19.3.4.5 Severe Overdosage 254
19.3.4.6 Chronic Therapy 254
19.3.5 Carbamazepine 254
19.3.6 Tricyclic Antidepressants 254
19.3.6.1 Blockade of Muscarinic Receptors 254
19.3.6.2 Blockade of Histamine H_1 Receptors 254
19.3.6.3 Blockade of α_1-Adrenoceptors 254
19.3.6.4 Blockade of 5-$HT_{2/1c}$ Receptors 254
19.3.6.5 Membrane Stabilization 254
19.3.6.6 Cardiovascular Side Effects 255
19.3.6.7 Allergic and Haematological Reactions 255
19.3.6.8 Endocrine Side Effects 255
19.3.6.9 Others 255
19.3.7 SSRIs 255
19.3.8 MAOIs 255
19.3.8.1 Dangerous Food Interactions 255
19.3.8.2 Dangerous Drug Interactions 255
19.3.8.3 Other Side Effects 255
19.3.9 Benzodiazepines 256
19.3.10 Buspirone 256
19.3.11 Disulfiram 256
19.3.12 Cyproterone Acetate 256
19.4 Official Guidance 256
19.4.1 Antipsychotic Doses above the BNF Upper Limit 256
19.4.2 Benzodiazepines 257
19.4.3 Prevention of Adverse Drug Reactions 257
19.5 Reporting 257
19.5.1 Britain 257

19.6 ADROIT 257
19.6.1 Newer Drugs 257
19.6.2 Established Drugs 257
Bibliography 258

Chapter 20 Genetics 259

20.1 DNA and the Double Helix 259
20.2 Chromosomes 259
20.2.1 Number 259
20.2.2 Karyotype 259
20.2.3 Centromere 259
20.2.4 Telomere 259
20.2.5 Metacentric Chromosomes 259
20.2.6 Acrocentric Chromosomes 259
20.2.7 Chromosomal Map 259
20.3 Autosomal Abnormalities 260
20.3.1 Down's Syndrome 260
20.3.2 Edward's Syndrome 261
20.3.3 Patau's Syndrome 261
20.3.4 Cri-du-Chat Syndrome 261
20.4 Sex Chromosome Abnormalities 261
20.4.1 Klinefelter's Syndrome 261
20.4.2 XYY Syndrome 261
20.4.3 Triple-X Syndrome 261
20.4.4 Tetra-X Syndrome 261
20.4.5 Turner Syndrome 261
20.4.6 Alzheimer's Disease 261
20.5 Cell Division 261
20.5.1 Mitosis 261
20.5.2 Meiosis 261
20.6 Gene Structure 261
20.7 DNA Replication 262
20.7.1 Transcription 262
20.7.2 Translation 263
20.8 Posttranslational Modification 263
20.9 Mutations 263
20.10 Techniques in Molecular Genetics 263
20.10.1 Restriction Enzymes 263
20.10.2 Gene Library 263
20.10.3 Molecular Cloning 264
20.10.4 Gene Probes 264
20.10.5 Oligonucleotide Probes 264
20.11 Polymerase Chain Reaction 264
20.12 Separating and Visualizing Different DNA Sequences 264
20.13 Restriction Fragment Length Polymorphism 264
20.14 Gel Electrophoresis 265
20.14.1 Southern Blotting 265
20.15 Genome-Wide Studies Using Microarray Technology 266
20.15.1 Recombination 266
20.15.2 Maximum Likelihood Score 266

20.16 Linkage Analysis 266
20.16.1 Genetic Markers 266
20.16.2 Linkage 266
20.16.3 Linkage Phases 266
20.16.4 Linkage Analysis 266
20.17 Quantitative Genetics 267
20.18 Basic Concepts of Quantitative Genetics 267
20.18.1 Pattern of Inheritance 267
20.18.1.1 Law of Uniformity 268
20.18.1.2 Mendel's First Law 268
20.18.1.3 Mendel's Second Law 268
20.19 Autosomal Dominant Inheritance 268
20.20 Autosomal Dominant Disorders 268
20.20.1 Huntington's Disease 268
20.20.2 Phacomatoses 268
20.20.3 Early-Onset Alzheimer's Disease 269
20.20.4 Other Autosomal Dominant Disorders 269
20.21 Autosomal Recessive Inheritance 269
20.22 X-Linked Recessive Inheritance 269
20.23 Autosomal Recessive Disorders 269
20.23.1 Disorders of Protein Metabolism 269
20.23.2 Disorders of Carbohydrate Metabolism and Lysosomal Storage 270
20.23.3 Other Disorders 271
20.24 X-Linked Dominant Inheritance 271
20.24.1 X-Linked Dominant Disorders 271
20.24.2 X-Linked Recessive Disorders 271
20.25 Other Concepts of Inheritance 271
20.25.1 Anticipation 271
20.25.2 Mosaicism 271
20.25.3 Uniparental Disomy 271
20.25.4 Genomic Imprinting 271
20.25.5 Mitochondrial Inheritance 271
20.26 Family Studies 271
20.26.1 Difficulties 272
20.27 Morbid Risk 272
20.28 Twin Studies 272
20.28.1 Methodology 273
20.28.2 Difficulties 274
20.29 Adoption Studies 274
20.29.1 Methodology 274
20.29.2 Difficulties 274
Acknowledgments 275
Bibliography 275

Chapter 21 Psychiatric Epidemiology 277

21.1 Disease Frequency 277
21.1.1 Incidence 277
21.1.1.1 Units 277
21.1.2 Prevalence 277
21.1.2.1 Units 277

21.1.3 Population at Risk 277
21.1.4 Chronicity 277
21.1.5 Steady-State Relationship between Point Prevalence and Incidence 277
21.2 Case Identification, Case Registers, and Mortality and Morbidity Statistics 278
21.2.1 Case Identification 278
21.2.1.1 Caseness 278
21.2.1.2 Classification 278
21.2.1.3 Screening 278
21.2.1.4 Likelihood Ratio 279
21.2.1.5 Pretest Odds 279
21.2.1.6 Posttest Odds 279
21.2.2 Case Registers 279
21.2.2.1 Mortality Statistics 279
21.2.2.2 Life Expectancy 279
21.3 Measurements of Risk 280
21.3.1 Relative Risk 280
21.3.2 Attributable Risk 281
21.3.3 Relative Risk Increase 281
21.3.4 Absolute Risk Reduction 281
21.3.5 Relative Risk Reduction 281
21.3.6 Number Needed to Treat 281
21.3.7 Odds Ratio 281
21.4 Study Design 282
21.4.1 Hierarchy of Research Methods 282
21.4.2 Confounding 282
References 303

Chapter 22 Biostatistics 305

22.1 Descriptive and Inferential Statistics 305
22.1.1 Descriptive Statistics 305
22.1.2 Inferential Statistics 305
22.1.3 Hypothesis Testing: Significance Tests 305
22.1.3.1 Null Hypothesis 305
22.1.3.2 Alternative Hypothesis 305
22.1.3.3 Simple Hypothesis 305
22.1.3.4 Composite Hypothesis 305
22.1.3.5 One-Sided Significance Test 305
22.1.3.6 Two-Sided Significance Test 305
22.1.3.7 Critical Region 305
22.1.3.8 Critical Value 305
22.1.3.9 Significance Level 305
22.1.3.10 Steps in Carrying Out a Significance/Hypothesis Test 306
22.1.4 Estimation: Confidence Intervals 306
22.1.5 Advantages of Confidence Intervals Over *p* Values 306
22.2 Specific Biostatistical Tests 307
22.2.1 *t*-Test 307
22.2.1.1 Independent Samples *t*-Test 307
22.2.1.2 Paired Samples *t*-Test 307
22.2.2 Chi-Square Test 307
22.2.2.1 Null Hypothesis 307

22.2.2.2 Calculation of χ^2 307
22.2.2.3 2 × 2 Contingency Table 308
22.2.2.4 Small Expected Values 308
22.2.2.5 Goodness of Fit 308
22.2.3 Fisher's Exact Probability Test 308
22.2.4 Mann–Whitney *U* Test 308
22.2.5 Confidence Interval for the Difference between Two Means 309
22.2.6 Confidence Interval for the Difference between Two Proportions 309
22.2.7 Confidence Interval for the Difference between Two Medians 309
22.2.7.1 Two Unpaired Samples 309
22.2.7.2 Two Paired Samples 309
22.3 More Complex Methods 309
22.3.1 Factor Analysis 309
22.3.2 Principal Components Analysis 309
22.3.3 Correspondence Analysis 310
22.3.4 Discriminant Analysis 310
22.3.5 Cluster Analysis 310
22.3.6 Multivariate Regression Analysis 310
22.3.7 Path Analysis 310
22.3.8 Canonical Correlation Analysis 310
22.4 Meta-Analysis, Survival Analysis, and Logistic Regression 310
22.4.1 Meta-Analysis 310
22.4.1.1 Definition 310
22.4.1.2 Difficulties 310
22.4.2 Survival Analysis 310
22.4.2.1 Survival Function 311
22.4.2.2 Survival Curve 311
22.4.2.3 Hazard Function 311
22.4.3 Logistic Regression 311
Bibliography 311

Chapter 23 Research Methodology and Critical Appraisal 313

23.1 Research Study Design 313
23.1.1 Types 313
23.1.2 Hierarchy of Evidence 313
23.1.3 Selection Process 313
23.2 Clinical Trials 313
23.2.1 Definition 313
23.2.2 Classification 314
23.2.3 Advantages of Randomized Trials 314
23.2.4 Disadvantages of Non-randomized Trials 315
23.2.4.1 Concurrent Controls 315
23.2.4.2 Historical Controls 315
23.3 Problems of Measurement in Psychiatry 316
23.3.1 Aims of Measurement 316
23.3.2 Problems of Measurement 316
23.3.3 Measurement Methods 316
23.3.4 Latent Traits (Constructs) 316
23.3.5 Reliability 316

23.3.5.1 Definition ... 316
23.3.5.2 Interrater Reliability ... 316
23.3.5.3 Intrarater Reliability ... 316
23.3.5.4 Test–Retest Reliability ... 316
23.3.5.5 Alternative Forms Reliability ... 317
23.3.5.6 Split-Half Reliability ... 317
23.3.6 Statistical Tests of Reliability ... 317
23.3.6.1 Percentage Agreement ... 317
23.3.6.2 Product–Moment Correlation Coefficient ... 317
23.3.6.3 Kappa Statistic ... 317
23.3.6.4 Intraclass Correlation Coefficient ... 317
23.3.6.5 Cronbach's Alpha ... 318
23.3.7 Validity ... 318
23.3.7.1 Definition ... 318
23.3.7.2 Face Validity ... 318
23.3.7.3 Content Validity ... 318
23.3.7.4 Predictive Validity ... 318
23.3.7.5 Concurrent Validity ... 318
23.3.7.6 Criterion Validity ... 318
23.3.7.7 Incremental Validity ... 318
23.3.7.8 Cross-Validity ... 318
23.3.7.9 Convergent Validity ... 318
23.3.7.10 Divergent Validity ... 318
23.3.7.11 Construct Validity ... 318
23.3.8 Type I Error ... 318
23.3.9 Type II Error ... 318
23.3.10 Power ... 318
23.3.11 Sensitivity ... 318
23.3.12 Specificity ... 319
23.3.13 ROC Curve ... 319
23.3.14 Predictive Values ... 319
23.3.15 Likelihood Ratios ... 319
23.3.16 Bias ... 319
23.3.16.1 Selection Bias ... 319
23.3.16.2 Observer Bias ... 319
23.3.16.3 Recall Bias ... 319
23.3.16.4 Information bias ... 320
23.3.16.5 Confounding bias ... 320
Bibliography ... 320

Chapter 24 Physical Therapies ... 321

24.1 Neurostimulation Therapies ... 321
24.2 Electroconvulsive Therapy ... 321
24.2.1 ECT Indications and Contraindications ... 321
24.2.1.1 Indications for ECT ... 321
24.2.1.2 Contraindications against ECT ... 321
24.2.1.3 Medications to Avoid before ECT ... 322
24.3 Preparation for ECT ... 322
24.4 Administration of ECT ... 322
24.4.1 Side Effects of ECT ... 325

24.5 Complications of ECT 326
24.6 Mortality 327
24.7 Repetitive Transcranial Magnetic Stimulation 327
24.7.1 Indications for rTMS 327
24.7.2 Mechanisms of rTMS 327
24.7.3 Efficacy of rTMS 327
24.8 Side Effects 327
24.8.1 ECT versus rTMS/MST 327
24.9 Vagal Nerve Stimulation 328
24.9.1 Indications for VNS 328
24.9.2 Mechanisms of Actions 328
24.9.3 Efficacy of VNS 328
24.9.4 Side Effects 328
24.10 Deep Brain Stimulation 328
24.11 Other Physical Therapies 328
24.11.1 Light Therapy/Phototherapy 328
24.11.1.1 Administration 329
24.11.1.2 Efficacy 329
24.11.1.3 Side Effects 329
24.11.2 Sleep Deprivation 329
24.11.2.1 Indications 329
24.11.2.2 Administration 329
24.11.3 Psychosurgery 329
24.11.3.1 Indications for Psychosurgery 329
24.11.3.2 Psychosurgery Practise 329
References 329

Chapter 25 Advanced Psychological Process and Treatment 331

25.1 Supportive Psychotherapy 331
25.1.1 Objectives 331
25.1.2 Historical Development 331
25.1.3 Characteristics 331
25.1.4 Indications 331
25.1.5 Contraindications 331
25.1.6 Techniques 331
25.2 Brief Dynamic Psychotherapy 333
25.2.1 Historical Development 333
25.2.2 Objectives 333
25.2.3 Indications 333
25.2.4 Contraindications 333
25.2.5 General Techniques 333
25.2.6 Subtypes of Brief Dynamic Psychotherapy 333
25.2.7 Negative Reactions During Brief Dynamic Psychotherapy 333
25.2.8 Structure 334
25.2.8.1 Initial Phase 334
25.2.8.2 Middle Phase 334
25.2.8.3 Terminal Phase 334
25.2.9 Case Vignette 334
25.2.10 Psychodynamic Formulation 334
25.2.11 CASC Preparation: Explain Brief Dynamic Psychotherapy to a Client 334

25.2.12 Research and Brief Psychodynamic Therapy 335
25.2.12.1 Structural Aspects 335
25.2.12.2 Methodological Aspects 336
25.2.12.3 Measurement of Outcomes 336
25.3 CBT 336
25.3.1 Historical Development of CBT 336
25.3.1.1 Cognitive Therapy 336
25.3.1.2 Behaviour Therapy 336
25.3.2 Objectives 336
25.3.3 Characteristics 336
25.3.4 Indications 336
25.3.5 Contraindications 336
25.3.6 Techniques 337
25.3.6.1 Cognitive Techniques 337
25.3.6.2 Behavioural Techniques 337
25.3.7 Socratic Questioning 337
25.3.8 During Each Session 337
25.3.9 Structure 337
25.3.9.1 Early Phase (Session 1–4) 337
25.3.9.2 Middle Phase (Session 5–12) 337
25.3.9.3 Termination (Session 13–16) 337
25.4 DBT 338
25.4.1 Historical Background 338
25.4.2 Objectives 338
25.4.3 Indications 338
25.4.4 Contraindications 338
25.4.5 Components of DBT 338
25.4.6 Techniques 338
25.5 Mentalization-Based Treatment 339
25.5.1 Historical Development 339
25.5.2 Objectives 339
25.5.3 Indications 339
25.5.4 Techniques 339
25.6 Cognitive Analytic Therapy 339
25.6.1 Historical Background 339
25.6.2 Objectives 339
25.6.3 Indications 339
25.6.4 Techniques 339
25.7 Interpersonal Therapy 340
25.7.1 Historical Background 340
25.7.2 Objectives 341
25.7.3 Indications 341
25.7.4 Techniques 341
25.7.4.1 Structure 341
25.7.5 CASC Preparation: Explain IPT to a Client 342
25.8 Family Therapy 343
25.8.1 Historical Perspectives 343
25.8.2 Indications 343
25.8.2.1 External Indicators for Family Therapy 343
25.8.2.2 Internal Indicators for Family Therapy 343
25.8.3 Assessment Techniques 343

25.8.4 Types of Family Therapy 343
25.8.4.1 Structural Family Therapy (Minuchin) 343
25.8.4.2 Systemic Family Therapy 344
25.8.4.3 Strategic Family Therapy 344
25.8.4.4 Eclectic Family Therapy 345
25.9 Group Therapy 345
25.9.1 Historical Development 345
25.9.2 Indications 345
25.9.3 Contraindications 345
25.9.4 Types of Group Therapy 346
25.9.4.1 Classification Based on Service Administration 346
25.9.4.2 Classification Based on Technique 346
25.10 Therapeutic Process 346
25.10.1 Pregroup Therapy Assessment 346
25.10.2 Yalom's 11 Therapeutic Factors 346
25.10.2.1 Early Stages 346
25.10.2.2 Middle Stage 347
25.10.2.3 End Stage 347
25.10.3 Role of the Therapist 347
25.10.4 Advantages of Group Therapy 347
25.10.5 Countertherapeutic Process 347
25.11 Couple Therapy 347
25.11.1 Objectives 347
25.11.2 Indications 347
25.11.3 Contraindications 347
25.11.4 Issues to Be Considered Before Arranging Couple Therapy 347
25.11.5 Types of Couple Therapy 348
25.11.6 Techniques of Couple Therapy 348
25.12 Motivational Interviewing 348
25.12.1 Indications 348
25.12.2 Techniques 348
25.12.3 Eye Movement and Desensitization Reprocessing 348
25.12.4 Grief Counselling 349
25.12.5 Approach to This CASC Station 349
25.12.5.1 Issues the Candidate Needs to Explore 349
25.13 Brief Insight-Oriented Therapy 349
25.14 Art Therapies 349
25.14.1 Types of Art Therapy 349
References 350

Chapter 26 Schizophrenia and Delusional Disorders 351

26.1 Schizophrenia 351
26.1.1 History 351
26.2 Classification of Schizophrenia 351
26.2.1 Schneiderian First-Rank Symptoms 351
26.2.2 St. Louis Criteria 352
26.2.3 Catego 352
26.2.4 Research Diagnostic Criteria 352
26.2.5 International Classification of Diseases, Tenth Revision: ICD-10 352
26.2.5.1 Subtypes 352

26.2.6 Type 1 and Type 2 Schizophrenia 355
26.2.7 SAPS and SANS 355
26.2.8 Liddle's Syndromes 355
26.2.8.1 Psychomotor Poverty Syndrome 355
26.2.8.2 Disorganization Syndrome 355
26.2.8.3 Reality Distortion Syndrome 355
26.2.9 Neurodevelopmental Classification 356
26.3 Epidemiology of Schizophrenia 358
26.3.1 Statistics 358
26.3.2 Theories 358
26.4 Aetiology of Schizophrenia 358
26.4.1 Genetics in Schizophrenia 358
26.4.1.1 Family Studies 358
26.4.1.2 Twin Studies 358
26.4.1.3 Adoption Studies 359
26.4.1.4 Linkage Studies 359
26.4.2 Prenatal Factors in Schizophrenia 359
26.4.3 Personality in Schizophrenia 360
26.4.4 Social Factors in Schizophrenia 360
26.4.4.1 Rural or Urban Setting 360
26.4.4.2 Ethnicity 360
26.4.4.3 Expressed Emotion 360
26.4.5 CASC Station on Schizophrenia and Cannabis 361
26.4.5.1 Approach to This Station 361
26.4.6 Neurotransmitters in Schizophrenia 361
26.4.6.1 Dopamine 361
26.4.6.2 Serotonin (5-HT) 362
26.4.6.3 Glutamate 362
26.4.7 Structural Cerebral Abnormalities in Schizophrenia 362
26.4.8 Neuropathological Abnormalities in Schizophrenia 363
26.4.8.1 Postmortem Studies 363
26.4.8.2 Histological Studies 363
26.4.9 Functional Brain Abnormalities in Schizophrenia 363
26.4.10 Deficits in Cognition in Schizophrenia 363
26.5 Management of Schizophrenia 364
26.5.1 Physical Examination 364
26.5.2 Investigations 364
26.5.3 General Management Strategies (Scottish Schizophrenia Guidelines and NICE Guidelines) 364
26.5.4 Promoting Recovery 365
26.5.4.1 Primary Care 365
26.5.4.2 Secondary Care 365
26.5.5 Service Interventions 365
26.5.6 Hospitalization 365
26.5.7 Drug Treatments for Schizophrenia 365
26.5.8 Use of Atypical Neuroleptics 366
26.5.8.1 NICE Guidelines on Atypical Antipsychotics 366
26.5.9 Treatment-Resistant Schizophrenia 366
26.5.9.1 Past Psychiatric History 366

26.5.9.2 Cross Sectional Measures....366
26.5.9.3 Prospective Trials....366
26.5.9.4 Clozapine Patient Management System....366
26.6 Medication Adherence....366
26.6.1 Psychosocial Treatments for Schizophrenia....367
26.6.1.1 General Principles....367
26.6.1.2 Psychoeducation....367
26.6.1.3 Social Milieu....368
26.6.1.4 Grief Work on Losses....368
26.6.1.5 Supportive Psychotherapy....369
26.6.1.6 Cognitive Behavioural Therapy....369
26.6.1.7 Expressed Emotion....369
26.6.1.8 Family Intervention....369
26.6.1.9 Art Therapy....369
26.6.1.10 Rehabilitation....369
26.6.2 Prognosis for Schizophrenia....370
26.6.2.1 Sociodemographics....370
26.6.2.2 Past History....370
26.6.2.3 Pathology....370
26.6.2.4 Course of Illness....370
26.6.2.5 Symptoms....370
26.6.2.6 Treatment....370
26.6.2.7 Suicide....370
26.6.2.8 Violence....370
26.6.3 Prodrome of Schizophrenia....370
26.6.3.1 Attenuated Positive Symptoms....370
26.6.3.2 Negative Symptoms....371
26.6.3.3 Cognitive Symptoms....371
26.6.3.4 General Symptoms....371
26.6.3.5 Interventions for Prodrome....371
26.6.3.6 Prognosis....371
26.6.3.7 Predictors for Further Progression to Psychosis or Schizophrenia....371
26.7 Catatonia....371
26.7.1 Aetiology....371
26.7.2 Clinical Features....371
26.7.3 Management....371
26.7.3.1 Investigations....371
26.7.4 Medications....371
26.7.5 Prognosis....372
26.8 Delusional (Paranoid) Disorders....372
26.8.1 ICD-10 Issues....372
26.8.2 Epidemiology of Delusional Disorders....372
26.8.3 Specific Delusional (Paranoid) Disorders....372
26.8.3.1 Pathological (Delusional) Jealousy....372
26.8.3.2 Erotomania (De Clérambault's Syndrome)....372
26.8.3.3 Cotard's Syndrome....372
26.8.3.4 Capgras Syndrome....372
26.8.3.5 Fregoli Syndrome....373
26.8.3.6 Induced Psychosis (Folie À Deux)....373

26.9 Schizoaffective Disorders....373
26.9.1 Types of Disorder....373
26.9.2 Relationship between Affective and Schizophrenic Components....373
26.9.3 Prognosis for Schizoaffective Disorders....373
References....374

Chapter 27 Mood Disorders, Suicide, and Parasuicide....377

27.1 History....377
27.2 Classifications of Mood Disorders....377
27.2.1 ICD-10 Classifications....377
27.2.1.1 F30 Manic Episode....377
27.2.1.2 F31 Bipolar Affective Disorder....377
27.2.2 DSM-5....377
27.2.2.1 ICD-10 Criteria for Depressive Episode (F32)....378
27.2.2.2 ICD-10 Criteria for Recurrent Depressive Disorder (F33)....379
27.2.2.3 ICD-10 Criteria for Dysthymia (F34)....379
27.2.3 Other Classifications of Depression....380
27.2.3.1 Endogenous versus Reactive Depression....380
27.2.3.2 Unipolar versus Bipolar Depression....380
27.2.3.3 Rapid-Cycling Bipolar Disorder....380
27.2.3.4 Other Classes....380
27.3 Epidemiology of Mood Disorders....383
27.3.1 Depressive Episodes....383
27.3.2 Bipolar Mood Disorder....384
27.4 Aetiology of Mood Disorders....384
27.4.1 Genetic Factors....384
27.4.1.1 Family Studies....384
27.4.1.2 Twin Studies....384
27.4.1.3 Adoption Studies....384
27.4.1.4 Molecular Genetics....384
27.4.2 Personality Factors in Mood Disorder....385
27.4.2.1 Cyclothymic Personality Disorder....385
27.4.2.2 Depressive Personality Disorder....385
27.4.3 Psychosocial Stressors in Mood Disorder....385
27.4.3.1 Childhood Factors....385
27.4.3.2 Adulthood Factors....385
27.4.3.3 Recent Life Events....385
27.4.4 Physical Illness in Mood Disorder....386
27.4.5 Psychological Factors in Mood Disorder....386
27.4.6 Neurotransmitters in Mood Disorder....388
27.4.6.1 Serotonin (5-HT)....388
27.4.6.2 Adaptive Changes in Receptors....389
27.4.6.3 Brain-Derived Neurotropic Factor....389
27.4.7 Neuroendocrine Factors in Mood Disorder....389
27.4.7.1 Brain–Steroid Axis....389
27.4.7.2 Brain–Thyroid Axis....389
27.4.7.3 Melatonin....389
27.4.7.4 Water and Electrolyte Changes....390
27.4.8 Neuroanatomy and Imaging....390
27.4.8.1 Structural Imaging....390

27.4.8.2 Bipolar Disorder 390
27.4.8.3 Functional Imaging....390
27.4.8.4 Bipolar Disorder 390
27.5 Management of Depressive Disorder 390
27.5.1 Investigations....390
27.5.2 Pharmacotherapy: NICE Guidelines....390
27.5.2.1 Unipolar Depression 390
27.5.2.2 Sequenced Treatment Alternatives to Relieve Depression Trial 392
27.5.2.3 Atypical Depression....392
27.5.2.4 Psychotic Depression 392
27.5.2.5 Resistant Major Depression 392
27.5.3 Electroconvulsive Therapy and Physical Therapies in Mood Disorder....394
27.5.4 Psychosocial Treatments 394
27.5.4.1 Psychotherapies....394
27.5.4.2 CASC Preparation: Explain CBT to a Depressed Person....394
27.5.4.3 NICE Guidelines Recommendations on CBT and Depressive Disorder.... 395
27.5.5 Management of Bipolar Disorder (NICE Guidelines Recommendations)....395
27.5.5.1 Investigations 395
27.5.5.2 Pharmacotherapy 396
27.5.5.3 Psychotherapy 396
27.5.5.4 Relapse Prevention....396
27.5.6 Management of Rapid Cycling....397
27.5.6.1 Prognosis for Mood Disorders....397
27.6 Persistent Mood Disorders....397
27.6.1 Cyclothymia 397
27.6.2 Dysthymia 397
27.7 Suicide and Parasuicide (Deliberate Self-Harm)....398
27.7.1 Suicide....398
27.7.1.1 Epidemiology....398
27.7.1.2 Aetiology of Suicide 398
27.7.1.3 Assessment of the Individual for Suicide 399
27.7.1.4 Management of Suicidal Ideation....399
27.7.2 Parasuicide 399
27.7.2.1 Epidemiology....399
27.7.2.2 Aetiology of Parasuicide....400
27.7.2.3 Assessment of the Individual for Suicide 400
27.7.2.4 Assessment of Risk Factors for Subsequent Completion of Suicide 401
27.7.2.5 Management of Parasuicide....401
References 401

Chapter 28 Neurotic and Stress-Related Disorders 405

28.1 History....405
28.2 Classifications of Neurosis 405
28.3 General Issues....405
28.3.1 Effect of Childhood Neurosis....405
28.3.2 Effect of Personality Disorder....405
28.3.3 Mortality....405
28.4 Phobic Anxiety Disorders 405
28.4.1 Epidemiology of Phobic Anxiety Disorder....405
28.4.2 Aetiology of Phobic Anxiety Disorder....407

28.4.2.1 Genetic Factors 407
28.4.2.2 Psychological Factors 407
28.4.2.3 Comorbidity 407
28.4.3 Management of Phobic Anxiety Disorder 407
28.4.3.1 Psychological Approaches 407
28.4.3.2 Pharmacological Approaches 407
28.4.4 Specific Phobic Disorders 407
28.4.4.1 Agoraphobia 407
28.4.4.2 Social Phobias 408
28.4.4.3 Isolated Phobias 408
28.5 Generalized Anxiety Disorder 409
28.5.1 Epidemiology of Generalized Anxiety Disorder 409
28.5.2 Aetiology of Generalized Anxiety Disorder 409
28.5.2.1 Genetic Factors 409
28.5.2.2 Neurochemistry 409
28.5.2.3 Endocrinology 409
28.5.2.4 Imaging 409
28.5.2.5 Cognitive Theories 409
28.5.2.6 Psychoanalytic Theories 409
28.5.2.7 Environmental Factors 409
28.5.3 Diagnostic Criteria 409
28.5.4 Medical Differential Diagnosis 410
28.5.5 Management of Generalized Anxiety Disorder 410
28.5.5.1 Psychological Therapies 410
28.6 Panic Disorder 413
28.6.1 Epidemiology of Panic Disorder 413
28.6.2 Aetiology of Panic Disorder 413
28.6.2.1 Genetic Factors 413
28.6.2.2 Cognitive Theories 413
28.6.2.3 Psychoanalytic Theories 413
28.6.2.4 Neurochemistry 413
28.6.2.5 Neuroimaging 414
28.6.2.6 Comorbidity 414
28.6.2.7 Life Events 414
28.6.2.8 Physiological Factors 414
28.6.3 Diagnostic Criteria 415
28.6.3.1 Diagnostic Criteria 415
28.6.4 Differential Diagnosis 415
28.6.4.1 Hyperventilation Syndrome 415
28.6.4.2 Medical Differential Diagnosis 415
28.6.5 Management of Panic Disorder 415
28.6.5.1 Pharmacotherapy 415
28.6.5.2 Psychological Treatment 416
28.7 OCD 416
28.7.1 Epidemiology of OCD 416
28.7.2 Aetiology of OCD 416
28.7.2.1 Genetic Factors 416
28.7.2.2 Neuroimaging 417
28.7.2.3 Neurological Factors 417

28.7.2.4 Psychological Factors 417
28.7.3 Diagnostic Criteria 417
28.7.3.1 ICD-10 (F42) 417
28.7.3.2 DSM-5 417
28.7.4 Management of OCD 418
28.7.4.1 Pharmacotherapy 418
28.7.4.2 Psychological Treatments 418
28.7.4.3 Physical Treatments 418
28.7.5 Course 418
28.8 OCD-Spectrum Disorders 422
28.8.1 Body Dysmorphic Disorder 422
28.8.1.1 Historical Development 422
28.8.1.2 Epidemiology 422
28.8.1.3 Aetiology 422
28.8.1.4 Clinical Features 422
28.8.1.5 Differential Diagnosis 423
28.8.1.6 Comorbidity 423
28.8.1.7 Management 423
28.9 Hoarding 425
28.9.1 Historical Development 425
28.9.1.1 Epidemiology 425
28.9.1.2 Aetiology 425
28.9.1.3 Clinical Features 426
28.9.1.4 Questionnaires 426
28.9.1.5 Differential Diagnosis 426
28.9.1.6 Psychiatric Comorbidity 426
28.10 Treatment 426
28.10.1 Psychological Treatment 426
28.10.1.1 Cognitive Behaviour Therapy 426
28.10.2 Pharmacological Treatment 426
28.10.3 Trichotillomania 426
28.10.3.1 ICD-10 Criteria 426
28.10.3.2 DSM-5 Criteria (312.39) 426
28.10.4 Skin Picking Disorder 426
28.11 Acute Stress Reaction 426
28.11.1 ICD-10 427
28.11.2 DSM-5 (308.3) 427
28.11.3 Management 427
28.12 PTSD 427
28.12.1 Aetiology of PTSD 427
28.12.1.1 General Factors 427
28.12.1.2 Biological Factors 427
28.12.1.3 Psychosocial Factors 427
28.12.2 Diagnostic Criteria 427
28.12.2.1 ICD-10 (F43.1) 427
28.12.2.2 DSM-5 (309.81) 428
28.12.3 Management of PTSD 428
28.12.3.1 Psychological Therapy 428

28.12.3.2 Pharmacotherapy 428
28.12.3.3 Eye Movement Desensitization Reprocessing 428
28.12.4 Course 428
28.13 Adjustment Disorders 432
28.13.1 ICD-10 (F43.2) 432
28.13.2 DSM-5 (APA 2013) 432
28.14 Dissociative (Conversion) Disorders 433
28.14.1 ICD-10 433
28.14.2 Specific Dissociative Conditions 433
28.14.2.1 Dissociative Amnesia 433
28.14.2.2 Dissociative Fugue 433
28.14.2.3 Dissociative Stupor 433
28.14.2.4 Trance and Possession Disorders 433
28.14.2.5 Dissociative Disorders of Movement and Sensation 433
28.14.2.6 Dissociative Convulsions 433
28.14.2.7 Dissociative Anaesthesia and Sensory Loss 434
28.14.2.8 Other Dissociative Disorders 434
28.14.3 Epidemiology of Dissociative Disorder 434
28.14.4 Aetiology of Dissociative Disorder 434
28.14.5 Management of Dissociative Disorder 434
28.14.6 Course 434
28.15 Depersonalization–Derealization 435
28.15.1 DSM-5 (300.6) 435
References 435

Chapter 29 Personality Disorders 437

29.1 History 437
29.2 Classification and Measurement 437
29.2.1 Dimensional Approach 437
29.2.1.1 Cattell's Trait Theory 437
29.2.1.2 Eysenck's Theory 437
29.2.1.3 Minnesota Multiphasic Personality Inventory 437
29.2.1.4 Rorschach Inkblot Test 437
29.2.1.5 Rotter's Internal–External Locus of Control 437
29.2.2 Categorical Approach 438
29.3 ICD-10 and Proposed DSM-5 Classifications 438
29.4 Statistics 438
29.5 Cluster A Personality Disorders 439
29.5.1 Schizoid Personality Disorder 439
29.5.1.1 Epidemiology 439
29.5.1.2 Aetiology 439
29.5.1.3 Diagnostic Criteria 440
29.5.1.4 Elicit Schizoid Personality in CASC 440
29.5.1.5 Differential Diagnosis 440
29.5.1.6 Management 440
29.5.1.7 Course 440
29.5.2 Schizotypal Disorder 440

29.5.2.1 Epidemiology 440
29.5.2.2 Aetiology 440
29.5.2.3 Clinical Features 441
29.5.2.4 Elicit Schizotypal Disorder in CASC 441
29.5.2.5 Differential Diagnosis 441
29.5.2.6 Management 441
29.5.2.7 Course and Prognosis 442
29.5.3 Paranoid Personality Disorder 442
29.5.3.1 Epidemiology 442
29.5.3.2 Aetiology 442
29.5.3.3 Clinical Features 442
29.5.3.4 Elicit Paranoid Personality Disorder in CASC 442
29.5.3.5 Differential Diagnosis 442
29.5.3.6 Management 443
29.5.3.7 Course and Prognosis 443
29.6 Cluster B Personality Disorders 443
29.6.1 Borderline Personality Disorder 443
29.6.1.1 Epidemiology 443
29.6.1.2 Aetiology 443
29.6.1.3 Clinical Features 444
29.6.1.4 Elicit Borderline Personality Disorder in CASC 444
29.6.1.5 Differential Diagnosis 444
29.6.2 Management 445
29.6.2.1 Inpatient Treatment and Therapeutic Communities 445
29.6.2.2 Psychotherapy 446
29.6.2.3 Pharmacotherapy 446
29.6.2.4 Course and Prognosis 447
29.6.3 Dissocial Personality Disorder 447
29.6.3.1 Epidemiology 447
29.6.3.2 Aetiology 447
29.6.3.3 Clinical Features 448
29.6.3.4 Elicit Dissocial Personality Disorder in CASC 448
29.6.3.5 Differential Diagnosis 449
29.6.3.6 Comorbidity 449
29.6.3.7 Management 449
29.6.3.8 Course and Prognosis 449
29.6.4 Narcissistic Personality Disorder 450
29.6.4.1 Epidemiology 450
29.6.4.2 Aetiology 450
29.6.4.3 Clinical Features 450
29.6.4.4 Elicit Narcissistic Personality Disorder in CASC 450
29.6.4.5 Differential Diagnosis 451
29.6.4.6 Comorbidity 451
29.6.4.7 Treatment 451
29.6.4.8 Course and Prognosis 451
29.6.5 Histrionic Personality Disorder 451
29.6.5.1 Epidemiology 451
29.6.5.2 Aetiology 451
29.6.5.3 Clinical Features 451

29.6.5.4 Elicit Histrionic Personality Disorder in CASC 451
29.6.5.5 Differential Diagnosis 452
29.6.5.6 Comorbidity 452
29.6.5.7 Treatment 452
29.6.5.8 Course and Prognosis 452
29.7 Cluster C Personality Disorders 452
29.7.1 Anankastic Personality Disorder 452
29.7.1.1 Epidemiology 452
29.7.1.2 Aetiology 452
29.7.1.3 Clinical Features 452
29.7.1.4 Elicit Anankastic Personality Disorder in CASC 453
29.7.1.5 Differential Diagnosis 453
29.7.1.6 Comorbidity 453
29.7.1.7 Management 453
29.7.1.8 Course and Prognosis 453
29.7.2 Anxious (Avoidant) Personality Disorder 453
29.7.2.1 Epidemiology 453
29.7.2.2 Aetiology 454
29.7.2.3 Clinical Features 454
29.7.2.4 Elicit Anxious (Avoidant) Personality Disorder in CASC 454
29.7.2.5 Differential Diagnosis 454
29.7.2.6 Comorbidity 454
29.7.2.7 Treatment 455
29.7.2.8 Course and Prognosis 455
29.7.3 Dependent Personality Disorder 455
29.7.3.1 Epidemiology 455
29.7.3.2 Aetiology 455
29.7.3.3 Clinical Features 455
29.7.3.4 Elicit Dependent Personality Disorder in CASC 455
29.7.3.5 Differential Diagnosis 455
29.7.3.6 Treatment 456
Bibliography 457

Chapter 30 Cross-Cultural Psychiatry 459

30.1 Basic Concepts 459
30.1.1 Cultural Assessment 459
30.2 International Comparisons 459
30.2.1 Schizophrenia 459
30.2.1.1 *International Pilot Study of Schizophrenia* 460
30.2.1.2 *Determinants of Outcome Study* 460
30.2.2 Neurosis 460
30.2.2.1 New Cross-Cultural Psychiatry 461
30.2.2.2 Translation and Validity of Rating Scales 461
30.2.2.3 Classificatory Systems 461
30.2.2.4 Culture-Bound Syndromes 461
30.3 Culture-Bound Syndromes in Asia 461
30.3.1 Amok 461
30.3.2 Latah 462
30.3.3 Koro 462
30.3.4 Dhat 462

30.3.5 Frigophobia....462
30.3.6 Taijinkyofusho....462
30.4 Culture-Bound Syndromes in America....462
30.4.1 Piblokto....462
30.4.2 Susto....462
30.4.3 Windigo....463
30.4.4 Uqamairineq....463
30.5 Culture-Bound Syndromes in Africa....463
30.5.1 Bouffee Delirante....463
30.5.2 Brain Fag Syndrome....463
30.5.3 Ufufuyane....463
30.5.4 Nerfiza....463
30.6 Psychiatry and Black and Ethnic Minorities in Britain....463
30.6.1 Immigrants....463
30.6.1.1 Types of Migrants....463
30.6.1.2 Stresses Involved in Migration....464
30.6.2 Mental Illness among Ethnic Minorities....464
30.6.2.1 Schizophrenia....464
30.6.2.2 Suicide....464
30.6.2.3 Other Countries....465
30.6.2.4 Child and Adolescent Psychiatric Presentations....465
30.6.3 Use of Psychiatric Services by Ethnic Minorities....465
30.6.3.1 Approaches to Management....466
References....466

Chapter 31 Liaison, Organic, and Neuropsychiatry....469

31.1 Liaison Psychiatry....469
31.1.1 Somatization Disorder....469
31.1.1.1 Epidemiology....469
31.1.1.2 Aetiology....469
31.1.1.3 Clinical Features....469
31.1.2 Somatoform Autonomic Dysfunction....470
31.1.3 Persistent Somatoform Pain Disorder....470
31.1.4 Hypochondriacal Disorder....470
31.1.4.1 Epidemiology....470
31.1.4.2 Aetiology....471
31.1.4.3 DSM-5....471
31.1.4.4 Management....471
31.1.4.5 Course and Prognosis....471
31.1.4.6 Conversion Disorder and Body Dysmorphic Disorder....471
31.2 Factitious Disorder and Malingering....471
31.2.1 Factitious Disorder....471
31.2.2 Factitious Disorder by Proxy....471
31.2.3 Malingering....471
31.3 Cardiology and Psychiatry....472
31.3.1 Antidepressant Trials in Patients Suffering from IHD....472
31.4 Nephrology and Psychiatry....473
31.4.1 Psychiatric Aspects of Chronic Renal Failure....473
31.4.2 Psychiatric Aspects of Dialysis....473

31.5 Hepatology and Psychiatry 475
31.5.1 Hepatic Encephalopathy 475
31.5.2 Wilson's Disease 475
31.5.3 Use of Psychotropic Drugs for Patients Suffering from Liver Diseases 475
31.6 Endocrinology and Psychiatry 476
31.6.1 Hyperthyroidism 476
31.6.2 Hypothyroidism 476
31.6.2.1 Aetiology 476
31.6.2.2 Neuropsychiatric Symptoms 476
31.6.2.3 Investigations 476
31.6.2.4 Treatment 476
31.6.3 Cushing's Syndrome 476
31.6.4 Addison's Disease 477
31.6.5 Syndrome of Inappropriate Antidiuretic Hormone Hypersecretion 477
31.6.6 Psychogenic Polydipsia 477
31.6.7 Diabetes Mellitus 477
31.6.8 Diabetes Insipidus 477
31.6.9 Hyperparathyroidism 478
31.6.10 Hypoparathyroidism 478
31.7 Oncology and Psychiatry 478
31.7.1 Side Effects of Chemotherapeutic Agents 479
31.7.2 Chronic Fatigue Syndrome 479
31.7.2.1 Epidemiology 479
31.7.2.2 Aetiology 479
31.7.2.3 Pathology 479
31.7.2.4 Diagnostic Criteria 479
31.7.2.5 Investigations 479
31.7.2.6 Management 480
31.7.2.7 Prognosis 480
31.8 Organic Psychiatry 481
31.8.1 Organic Mental Disorders 481
31.8.1.1 Organic Hallucinosis 482
31.8.1.2 Organic Mood Disorder 482
31.8.1.3 Organic Anxiety Disorder 482
31.8.1.4 Organic Catatonic Disorder 483
31.8.1.5 Organic Delusional or Schizophrenia-Like Disorder 483
31.8.1.6 Organic Personality Disorder 483
31.9 Neuropsychiatric Aspects of Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome 484
31.9.1 Introduction 484
31.9.1.1 Epidemiology of HIV/AIDS in the United Kingdom 484
31.9.2 Human Immunodeficiency Virus 484
31.9.3 Diagnosis of HIV Infection and Counseling 484
31.9.4 Antiretroviral Treatment 485
31.9.5 Psychiatric Disorders and HIV Infection 485
31.9.5.1 Acute Stress Reaction 485
31.9.5.2 Adjustment Disorder 485
31.9.5.3 Depressive Disorder 485
31.9.5.4 Mania 486
31.9.5.5 Cognitive Impairment and Dementia 487
31.9.6 Differential Diagnosis 488

31.9.7 Management....488
31.9.7.1 Investigations....488
31.9.7.2 Treatment....488
31.10 Neuropsychiatric Aspects of Parkinson's Disease....488
31.10.1 Introduction....488
31.10.1.1 Pathophysiology of Parkinson's Disease....488
31.10.1.2 Clinical Features of PKD....488
31.10.1.3 Treatment of PKD....489
31.10.2 Psychiatric Disorders and PKD....489
31.10.2.1 Depression....489
31.10.2.2 Mania....490
31.10.2.3 Anxiety....490
31.10.2.4 Psychosis....490
31.10.2.5 Sleep Disturbances....491
31.10.2.6 Cognitive Impairment and Dementia....491
31.11 Neuropsychiatric Aspects of Cerebrovascular Accident....491
31.11.1 Introduction....491
31.11.1.1 Types of Cerebrovascular Accident....491
31.11.1.2 Psychiatric Disorders and Cerebrovascular Accident....491
31.12 Neuropsychiatric Aspects of Epilepsy....494
31.12.1 Introduction....494
31.12.1.1 Classification of Epilepsy....494
31.13 Psychiatric Aspects of Epilepsy....496
31.13.1 Epidemiology....496
31.13.1.1 Psychiatric Comorbidity of Epilepsy....496
31.13.1.2 Psychiatric Conditions and Epilepsy....496
31.13.2 Psychotropic Medications and Epilepsy....496
31.14 Neuropsychiatric Aspects of Head Injury....496
31.14.1 Epidemiology....496
31.14.1.1 Head Injury....496
31.14.1.2 Neuropsychiatric Sequelae of Head Injury....498
31.14.1.3 Aetiological Factors and Severity of Head Injury....498
31.14.1.4 Mild Head Injury....499
31.14.1.5 Moderate Head Injury....499
31.14.1.6 Severe Head Injury....499
31.14.2 Postconcussion Syndrome....499
31.14.3 Posttraumatic Amnesia....499
31.14.3.1 Intracranial Pressure and Head Injury....499
31.14.3.2 Imaging and Head Injury....500
31.14.3.3 Neuropsychiatric Sequelae of Frontal Lobe Injury....500
31.15 Neuropsychiatric Sequelae of Haematoma....500
31.15.1 Rehabilitation of Patients Suffering from Head Injury....501
31.16 Neuropsychiatric Aspects of Brain Tumour....501
31.16.1 Multiple Sclerosis....501
31.16.1.1 Epidemiology....501
31.16.1.2 Pathology....501
31.16.1.3 Clinical Features....502
31.16.1.4 Psychiatric Manifestations....502
31.16.1.5 Cognitive Impairments....502
31.16.1.6 Management of Neuropsychiatric Conditions Associated with MS....502

31.17 Neuropsychiatric Aspects of Lyme Disease 502
31.17.1 Neurosyphilis 503
31.18 Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections 503
31.18.1 Epidemiology 503
31.18.2 Pathophysiology 503
31.18.3 Clinical Features 503
31.18.4 Investigations 504
31.18.5 Treatment 504
References 506

Chapter 32 Addiction and Psychoactive Substance Use Disorders 507

32.1 Classification and Definitions 507
32.1.1 DSM-5 507
32.1.2 Acute Intoxication 507
32.1.3 Harmful Use 507
32.1.4 Dependence Syndrome 508
32.1.5 Withdrawal State 508
32.1.6 Withdrawal State with Delirium 508
32.1.7 Psychotic Disorder 509
32.1.8 Amnesic Syndrome 509
32.1.9 Residual and Late-Onset Psychotic Disorder 509
32.2 Alcohol: The Chemical and Pharmacological Properties 509
32.2.1 Unit of Alcohol 509
32.2.2 Levels of Consumption 510
32.2.3 Mechanism of Action 510
32.2.4 Adverse Effects of Alcohol on Physical Health 512
32.2.4.1 Nervous System 513
32.2.4.2 Cardiovascular System 513
32.2.4.3 Gastrointestinal Disorders 513
32.2.4.4 Malnutrition 513
32.2.4.5 Liver 513
32.2.4.6 Pancreas 514
32.2.4.7 Electrolyte Disturbance 514
32.2.4.8 Endocrine and Sexual Disorders 514
32.2.4.9 Blood 514
32.2.4.10 Infections 514
32.2.4.11 Metabolism 515
32.2.4.12 Neoplasms 515
32.2.4.13 Early Death 515
32.2.4.14 Trauma 515
32.2.4.15 Pregnancy 515
32.2.5 Adverse Effects of Alcohol on Mental Health 516
32.2.5.1 Organic Brain Syndromes 516
32.2.6 Adverse Effect of Alcohol on Social Functions 519
32.3 Alcohol Consumption and Misuse 519
32.3.1 Epidemiology of Alcohol Consumption and Misuse 519
32.3.2 Aetiology of Alcohol Consumption and Misuse 519

32.3.2.1 Genetic Factors 519
32.3.2.2 Biological Factors 520
32.3.2.3 Psychological Factors 520
32.3.2.4 Psychiatric Illness 520
32.3.2.5 Personality Factors 520
32.3.2.6 Social Factors 520
32.3.2.7 Cultural Factors 521
32.3.2.8 Religion 521
32.3.3 Diagnosis of Alcohol Intoxication and Dependence 521
32.3.4 Management 521
32.3.4.1 Clinical Assessment 521
32.3.4.2 Investigations 521
32.3.5 Management on Withdrawal and Detoxification 523
32.3.6 Maintenance of Abstinence 524
32.4 Pharmacological Treatments 524
32.4.1 Disulfiram 524
32.4.1.1 Mechanism of Action 524
32.4.1.2 Aversive Effects with Ingestion of Alcohol 525
32.4.1.3 Dosage 525
32.4.1.4 Side Effects 525
32.4.1.5 Drug Interactions and Contraindication 525
32.4.2 Acamprosate 525
32.4.2.1 Mechanism of Action 525
32.4.2.2 Dosage 525
32.4.2.3 Side Effects 526
32.4.2.4 Drug Interactions and Contraindications 526
32.4.3 Naltrexone 526
32.4.3.1 Medical Use 526
32.4.3.2 Mechanism of Action 526
32.4.3.3 Dosage 526
32.5 Psychological Treatments 526
32.5.1 Alcoholics Anonymous 526
32.5.2 Other Psychological Treatments 527
32.5.3 Clinical Trials 527
32.5.3.1 Prognosis 527
32.6 Nonalcoholic Psychoactive Substances: Legal Aspects in the United Kingdom 529
32.6.1 Misuse of Drug Regulations 2001 529
32.6.2 Misuse of Drugs Act 1971 (Modification) Order 2003 and Misuse of Drugs Regulations 2003 529
32.6.3 Prescribing Controlled Drugs 530
32.6.4 Opioids 530
32.6.4.1 Heroin (Gear, Smack, Scag) 531
32.6.4.2 Epidemiology 531
32.6.4.3 Drug Action 531
32.6.4.4 Effects of Opioid Withdrawal 531
32.6.4.5 Harmful Effects 531
32.6.5 Codeine 533
32.6.5.1 Management of Opiate/Opioid Dependence 533
32.6.6 Methadone 535
32.6.6.1 Indications 535

32.6.6.2 Contraindications 535
32.6.6.3 Properties of Methadone 535
32.6.6.4 Administration 535
32.6.6.5 Dose 535
32.6.6.6 Duration of Maintenance Treatment 535
32.6.6.7 Treatment Setting 536
32.6.6.8 Management of Methadone Overdose 536
32.6.6.9 Cardiovascular Risks 536
32.6.6.10 Management of Pain 536
32.6.7 Buprenorphine 536
32.6.7.1 Indications 536
32.6.7.2 Pharmacodynamics 536
32.6.7.3 Pharmacokinetics 536
32.6.7.4 Dosage 537
32.6.7.5 Side Effects 537
32.6.7.6 Contraindications 537
32.6.7.7 Withdrawal of Buprenorphine 537
32.6.7.8 Diversion 537
32.6.7.9 Antagonist Treatment 538
32.6.7.10 Psychosocial Intervention 538
32.6.7.11 Psychological Methods 538
32.6.7.12 Motivational Interviewing 538
32.6.7.13 Relapse Prevention 538
32.6.7.14 Prognosis 538
32.6.8 Cannabis (Grass, Hash, Ganja, Pot) 538
32.6.8.1 Mechanism of Actions 538
32.6.8.2 Cannabinoid Receptors 538
32.6.8.3 Clinical Features 539
32.6.8.4 Drug Withdrawal 540
32.6.8.5 Harmful Effects 540
32.6.8.6 Treatment 540
32.6.9 Stimulants 540
32.6.9.1 Cocaine (Coke, Snow, Crack) 540
32.6.9.2 Epidemiology 540
32.6.9.3 Drug Action 540
32.6.9.4 Routes of Administration 541
32.6.9.5 Clinical Features 541
32.6.9.6 Cocaine Withdrawal 541
32.6.9.7 Harmful Effects 541
32.6.9.8 Pharmacological Treatment 542
32.6.9.9 Prognosis 542
32.6.10 Course 542
32.6.10.1 Amphetamines (Speed, Whizz, Sulphate) 542
32.6.10.2 Clinical Features 542
32.6.10.3 Treatment 542
32.6.11 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy, XTC, E, Adam) 543
32.6.11.1 Background 543
32.6.11.2 Chemical Properties 543
32.6.11.3 Administration 543
32.6.11.4 Clinical Effects 543

32.6.11.5 Other Harmful Effects 543
32.6.11.6 Management 544
32.6.12 Caffeine 544
32.6.12.1 Chemical Properties 544
32.6.12.2 Mechanisms of Actions of Caffeine 544
32.6.12.3 Dose and Clinical Effects 544
32.6.12.4 Other Systemic Effects of Caffeine 544
32.6.12.5 Dependence and Withdrawal 544
32.6.13 Hallucinogens 544
32.6.13.1 Epidemiology 545
32.6.13.2 Route of Administration 545
32.6.13.3 Clinical Effects 545
32.6.13.4 Treatment 545
32.6.14 Lysergic Acid Diethylamide (LSD, Trips, Acid, Microdots, Supermans) 545
32.6.14.1 Chemical Properties 545
32.6.14.2 Route of Administration 545
32.6.14.3 Drug Action 545
32.6.14.4 Drug Withdrawal 546
32.6.14.5 Harmful Effects 546
32.6.14.6 Clinical Effects 546
32.6.15 Hallucinogenic Mushrooms (Magic Mushrooms) 546
32.6.16 Mescaline 546
32.6.17 Phencyclidine (PCP, Angle Dust) 546
32.6.17.1 Chemical Properties 546
32.6.17.2 Neurochemical Effects 546
32.6.17.3 Clinical Effects 546
32.6.18 Ketamine (K) 547
32.6.19 Sedatives 547
32.6.20 Benzodiazepines 547
32.6.20.1 Epidemiology 547
32.6.20.2 Drug Action 547
32.6.20.3 Drug Withdrawal 547
32.6.20.4 Harmful Effects 548
32.6.20.5 Management 548
32.6.21 Barbiturates 548
32.6.21.1 Drug Action 548
32.6.21.2 Drug Withdrawal 548
32.6.21.3 Harmful Effects 548
32.6.21.4 Management 548
32.6.22 Nicotine 548
32.6.22.1 Epidemiology 548
32.6.22.2 Pharmacodynamics 549
32.6.22.3 Pharmacokinetics 549
32.6.22.4 Clinical Effects 549
32.6.22.5 Tobacco Withdrawal Syndrome 549
32.6.22.6 Pharmacological Treatment 549
32.6.22.7 Nicotine Replacement Therapy 549
32.6.22.8 Prognosis 550
32.6.23 Volatile Solvents 550
32.6.23.1 Drug Action 550

32.6.23.2 Drug Withdrawal 550
32.6.23.3 Harmful Effects 550
32.6.23.4 Management 550
32.6.23.5 Khat 550
32.6.23.6 Anabolic Steroid 550
32.7 Addiction without Substances 550
32.7.1 Pathological Gambling 550
32.7.1.1 Epidemiology 550
32.7.1.2 Aetiology and Risk Factors 551
32.7.1.3 Clinical Features 551
32.7.1.4 Management 551
32.8 Internet Addiction 552
32.8.1 Historical Development 552
32.8.2 Epidemiology 552
32.8.3 Aetiology and Risk Factors 552
32.8.3.1 Biological Theories 552
32.8.3.2 Psychological Theories 552
32.8.4 Clinical Features 552
32.8.4.1 Young's Definition 552
32.8.4.2 Proposed Criteria 552
32.8.5 Subtype of Internet Addiction 553
32.8.6 Psychiatric Comorbidity 553
32.8.7 Medical Complications 553
32.8.8 Management 553
32.8.8.1 Psychological Treatment 553
32.8.8.2 Pharmacological Treatment 553
32.8.8.3 Prognosis 553
References 553

Chapter 33 Disorders Specific to Women and Perinatal Psychiatry 557

33.1 Premenstrual Syndrome 557
33.1.1 Epidemiology of PMS 557
33.1.2 Aetiology of PMS 557
33.1.2.1 Genetic Factors 557
33.1.2.2 Neuroendocrine Factors 557
33.1.2.3 Neurophysiological Factors 557
33.1.2.4 Personality Factors 558
33.1.2.5 Psychological Factors 558
33.1.3 Symptoms of PMS 558
33.1.4 Management of PMS 558
33.1.4.1 Nonpharmacological Treatment 558
33.1.4.2 Pharmacological Treatment 558
33.2 Cyclic Psychosis 559
33.3 Pregnancy 559
33.3.1 Miscarriage 559
33.3.1.1 Consequences of Miscarriage 559
33.3.2 Termination of Pregnancy 560
33.3.3 Mental Disorders in Pregnancy 560
33.3.3.1 Minor Mental Illness 560
33.3.3.2 Major Mental Illness 560

33.4 Puerperal Disorders 566
33.4.1 General Issues 566
33.4.2 Postnatal Blues 566
33.4.2.1 Epidemiology 566
33.4.2.2 Aetiology 566
33.4.2.3 Clinical Features 567
33.4.2.4 Management 567
33.4.3 Postnatal Depression 567
33.4.3.1 Epidemiology 567
33.4.3.2 Aetiology 567
33.4.3.3 Clinical Features 567
33.4.3.4 Management 568
33.4.3.5 Outcome 568
33.4.4 Puerperal Psychosis 568
33.4.4.1 Epidemiology 568
33.4.4.2 Aetiology 569
33.4.4.3 Management 569
33.4.4.4 Course 570
33.4.5 Breast-Feeding and Psychotropic Medication 570
33.5 Menopause 573
33.5.1 Aetiology 573
33.5.1.1 Biological Factors 573
33.5.1.2 Psychological Factors 573
33.5.1.3 Social Factors 573
33.5.2 Clinical Features 573
33.5.3 Management 573
References 573

Chapter 34 Eating Disorders and Metabolic Syndrome 575

34.1 Anorexia Nervosa 575
34.1.1 Epidemiology 575
34.1.2 Aetiology 575
34.1.2.1 Genetic Factors 575
34.1.2.2 Biological Factors 575
34.1.2.3 Psychological Factors 576
34.1.2.4 Environmental Factors 576
34.1.3 Classification 577
34.1.3.1 ICD-10 (F50.0 Anorexia Nervosa) 577
34.1.3.2 DSM-5 (Anorexia Nervosa) 577
34.1.4 Differential Diagnosis of Anorexia Nervosa 577
34.1.5 Clinical Features 577
34.1.5.1 Psychological Symptoms and Signs 577
34.1.5.2 Physical Signs and Complications 578
34.1.6 Baseline Monitoring and Investigations 578
34.1.6.1 Baseline Monitoring 578
34.1.6.2 Full Blood Count 578
34.1.6.3 Electrolyte Disturbances 579
34.1.6.4 Arterial Blood Gas 579
34.1.6.5 Renal Function Tests 579

34.1.6.6 Liver Function Tests 579
34.1.6.7 Fasting Blood 579
34.1.6.8 Others 579
34.1.6.9 Hormones 579
34.1.6.10 Imaging 579
34.1.7 Management 579
34.1.7.1 Treatment Setting 579
34.1.7.2 Weight Restoration 579
34.1.7.3 Feeding 580
34.1.7.4 Managing Risk 580
34.1.7.5 Psychotherapy 580
34.1.7.6 Pharmacotherapy 581
34.1.8 Prognosis 581
34.2 Bulimia Nervosa 584
34.2.1 Epidemiology 584
34.2.2 Aetiology of Bulimia Nervosa 584
34.2.2.1 Genetic Factors 584
34.2.2.2 Biological Factors 584
34.2.2.3 Psychological Factors 584
34.2.2.4 Environmental Factors 584
34.2.3 Classification 585
34.2.3.1 ICD-10 (F50.2 Bulimia Nervosa) 585
34.2.3.2 DSM-5 (Bulimia Nervosa) 585
34.2.3.3 DSM-5 (Binge-Eating Disorder) 585
34.2.4 Differential Diagnosis of Bulimia Nervosa 585
34.2.5 Clinical Features of Bulimia Nervosa 585
34.2.5.1 Psychological Symptoms and Signs 585
34.2.5.2 Physical Signs and Complications 586
34.2.6 Management 586
34.2.6.1 Psychotherapy 586
34.2.6.2 Cognitive–Behavioural Therapy for BN 586
34.2.6.3 Interpersonal Therapy 587
34.2.6.4 Pharmacotherapy 587
34.2.7 Prognosis 587
34.3 Metabolic Syndrome 587
34.3.1 Epidemiology 587
34.3.2 Psychiatric Diseases and MetS 587
34.3.2.1 Schizophrenia 587
34.3.2.2 Depressive Disorder 587
34.3.2.3 Bipolar Disorder 587
34.3.3 Classification 588
34.3.4 Management 589
34.4 DSM-5 589
References 589

Chapter 35 Sexual Disorders 591

35.1 History 591
35.1.1 British Sexual Behaviour and Attitudes 591
35.1.2 First Heterosexual Intercourse 591

35.1.3 Heterosexual Partnerships 591
35.1.4 Heterosexual Practices 591
35.1.5 Sexual Diversity and Homosexual Behaviour 592
35.1.6 Sexual Attitudes 592
35.1.7 Physical Health 592
35.1.8 Perceived Risk 592
35.2 Sexual Response Cycle 592
35.3 Sexual Dysfunction 593
35.3.1 ICD-10 Classification 593
35.3.2 DSM-5 Classification 593
35.3.3 Sensate-Focus Therapy 593
35.4 Erectile Dysfunction 594
35.4.1 Normal Physiology 594
35.4.2 Epidemiology of Erectile Dysfunction 594
35.4.3 Aetiology of Erectile Dysfunction 594
35.4.3.1 Organic Causes 594
35.4.3.2 Pharmacological Factors 595
35.4.3.3 Psychological Factors 595
35.4.4 Assessment of Erectile Dysfunction 595
35.4.5 Diagnostic Criteria 595
35.4.5.1 DSM-5 Criteria: 302.72 Erectile Disorder 596
35.4.6 Investigations 596
35.4.7 Management of Erectile Dysfunction 596
35.4.7.1 Objectives 596
35.4.7.2 First-Line Treatment 596
35.4.7.3 Second-Line Treatment 598
35.4.7.4 Third-Line Treatment 599
35.5 Failure of Genital Responses for Women 599
35.6 Lack of Sexual Drive or Sexual Enjoyment 599
35.6.1 Aetiology and Risk Factors 599
35.6.2 Diagnostic Criteria 599
35.6.2.1 ICD-10 Criteria 599
35.6.2.2 DSM-5 Criteria 599
35.6.3 Treatment 600
35.7 Premature Ejaculation 600
35.7.1 Normal Physiology 600
35.7.2 Epidemiology of Premature Ejaculation 600
35.7.3 Aetiology of Premature Ejaculation 600
35.7.3.1 Nonphysical Factors 600
35.7.3.2 Physical Factors 600
35.7.4 Diagnostic Criteria 600
35.7.4.1 ICD-10 Criteria: F52.4 Premature Ejaculation 600
35.7.4.2 DSM-5 Criteria: 302.75 Early Ejaculation 600
35.7.5 Management of Premature Ejaculation 601
35.8 Anorgasmia 601
35.8.1 Normal Physiology 601
35.8.2 Epidemiology of Anorgasmia 601
35.8.3 Aetiology of Anorgasmia 601
35.8.3.1 Physical Factors 601
35.8.3.2 Psychological Factors 601
35.8.4 Diagnostic Criteria 601

35.8.4.1 ICD-10 Criteria: F52.3 Orgasmic Dysfunction 601
35.8.4.2 DSM-5 Criteria 601
35.8.5 Management of Anorgasmia 602
35.9 Vaginismus and Dyspareunia 602
35.9.1 Normal Physiology 602
35.9.2 Epidemiology of Vaginismus 602
35.9.3 Aetiology of Vaginismus 602
35.9.4 Diagnostic Criteria 602
35.9.4.1 ICD-10 Criteria 602
35.9.5 Management of Vaginismus 603
35.10 Disorders of Gender Identity 603
35.10.1 Classification 603
35.10.1.1 Transsexualism 603
35.10.1.2 Dual-Role Transvestism 603
35.10.1.3 Gender Identity Disorder of Childhood 603
35.10.2 Diagnostic Criteria 603
35.10.2.1 ICD-10 603
35.10.3 Treatment of Disorders of Gender Identity 604
35.11 Sexual Deviation 604
35.11.1 Classification 604
35.11.1.1 ICD-10 F65.0 Fetishism/DSM-5 302.81 Fetishistic Disorder 604
35.11.1.2 ICD-10 F65.1 Fetishistic Transvestism/DSM-5 302.3 Transvestic Disorder 604
35.11.1.3 F64.1 Dual-Role Transvestism 604
35.11.1.4 ICD-10 F65.2 Exhibitionism/DSM-5 302.4 Exhibitionistic Disorder 605
35.11.1.5 ICD-10 F65.3 Voyeurism/DSM-5 302.82 Voyeuristic Disorder 605
35.11.1.6 ICD-10 F65.4 Paedophilia/DSM-5 302.2 Paedophilic Disorder 605
35.11.1.7 ICD-10 F65.5 Sadomasochism/DSM-5 302.83 Sexual Masochism Disorder and 302.84 Sexual Sadism Disorder 605
35.11.1.8 DSM-5 302.89 Frotteuristic Disorder 605
35.11.2 Multiple Disorders of Sexual Preference 605
35.11.3 Other Disorders of Sexual Preference 605
35.12 Sexual Orientation 606
35.13 Antisocial Sexual Behaviour 606
35.13.1 Specific Antisocial Sexual Behaviours 606
35.13.1.1 Rape 606
35.13.1.2 Paedophilia 606
35.13.1.3 Incest 606
35.13.1.4 Indecent Exposure 607
35.13.1.5 Others 607
35.13.2 Treatment of Antisocial Sexual Behaviour 607
35.14 Sex Offender Treatment Programme 607
35.15 Pharmacological Treatment 607
References 610

Chapter 36 Sleep Disorders 613

36.1 Classification 613
36.2 Dyssomnias 613
36.2.1 Insomnia 613
36.2.1.1 Epidemiology 613
36.2.1.2 Aetiology 613

36.2.1.3 Clinical Features ... 613
36.2.1.4 Diagnostic Criteria ... 613
36.2.1.5 Differential Diagnosis ... 614
36.2.1.6 Management ... 614
36.2.1.7 Course and Prognosis ... 615
36.2.2 Hypersomnia ... 615
36.2.2.1 Epidemiology ... 615
36.2.2.2 Aetiology ... 615
36.2.2.3 Clinical Features ... 615
36.2.2.4 Diagnostic Criteria ... 615
36.2.2.5 Differential Diagnosis ... 615
36.2.2.6 Assessment and Investigations ... 615
36.2.2.7 Management ... 616
36.2.2.8 Course and Prognosis ... 616
36.2.3 Narcolepsy (Hypocretin Deficiency) ... 616
36.2.3.1 Epidemiology ... 616
36.2.3.2 Aetiology ... 616
36.2.3.3 Clinical Features ... 616
36.2.3.4 Management ... 616
36.2.3.5 Course ... 617
36.3 Breathing-Related Sleep Disorder ... 617
36.3.1 Obstructive Sleep Apnoea ... 617
36.3.1.1 Epidemiology ... 617
36.3.1.2 Risk Factors ... 617
36.3.1.3 Other Clinical Features ... 617
36.3.1.4 Management ... 617
36.3.2 Central Sleep Apnoea ... 617
36.3.2.1 Epidemiology ... 617
36.3.2.2 Risk Factors ... 617
36.3.2.3 Other Clinical Features ... 617
36.3.2.4 Management ... 617
36.3.3 Disorders of the Sleep–Wake Cycle ... 618
36.3.3.1 Epidemiology ... 618
36.3.3.2 Aetiology ... 618
36.3.3.3 Diagnostic Criteria ... 618
36.3.3.4 Management ... 618
36.3.3.5 Course and Prognosis ... 618
36.3.4 Restless Leg Syndrome ... 618
36.3.4.1 Epidemiology ... 618
36.3.4.2 Aetiology ... 618
36.3.4.3 DSM-5 Criteria ... 618
36.3.4.4 Other Clinical Features ... 619
36.3.4.5 Management ... 619
36.3.5 Parasomnias ... 619
36.4 Non-REM Parasomnias ... 619
36.4.1 Somnambulism (Sleepwalking) ... 619
36.4.1.1 Epidemiology ... 619
36.4.1.2 Aetiology and Risk Factors ... 619
36.4.1.3 ICD-10 Criteria ... 619
36.4.1.4 DSM-5 Criteria ... 619
36.4.1.5 Other Clinical Features ... 619

36.4.1.6 Differential Diagnosis....620
36.4.1.7 Management....620
36.4.2 Sleep Terrors (Night Terrors)....620
36.4.2.1 Epidemiology....620
36.4.2.2 Aetiology....620
36.4.2.3 ICD-10 Criteria....620
36.4.2.4 DSM-5 Criteria....620
36.4.2.5 Other Clinical Features....620
36.4.2.6 Differential Diagnosis....620
36.4.2.7 Management....620
36.4.2.8 Course and Prognosis....620
36.5 REM Parasomnias....620
36.5.1 Nightmares....620
36.5.1.1 Epidemiology....620
36.5.1.2 Aetiology....621
36.5.1.3 ICD-10 Criteria....621
36.5.1.4 DSM-5 Criteria....621
36.5.1.5 Other Clinical Features....621
36.5.1.6 Differential Diagnosis....621
36.5.1.7 Management....621
36.5.2 REM Sleep Behaviour Disorder....621
36.5.2.1 Epidemiology....621
36.5.2.2 Aetiology....621
36.5.2.3 DSM-5 Criteria....621
36.5.2.4 Management....621
References....622

Chapter 37 Child and Adolescent Psychiatry....623

37.1 Epidemiology....623
37.1.1 Preschool....623
37.1.2 Middle Childhood....623
37.1.3 Adolescence....623
37.2 Assessment....623
37.3 Pervasive Developmental Disorders....623
37.3.1 Childhood Autism (ICD-10 F84.0)/Autistic Disorder (DSM-5 299.0)....623
37.3.1.1 Historical Development....623
37.3.1.2 Epidemiology....623
37.3.1.3 Aetiology....623
37.3.1.4 Pathogenesis and Neurobiology....624
37.3.1.5 Theory of Mind....624
37.3.1.6 ICD-10 Diagnostic Criteria and Clinical Characteristics....624
37.3.1.7 Differences between the ICD-10 and DSM-5 Criteria....625
37.3.2 NICE Guidelines....625
37.3.2.1 Neurodevelopmental Disorders....625
37.3.2.2 Mental and Behavioural Disorders....625
37.3.2.3 Other Conditions....626
37.3.2.4 Physical Examination....626
37.3.2.5 Investigations....626
37.3.2.6 Comorbidity....626

37.3.2.7 Treatment 627
37.3.2.8 Course of Illness 628
37.3.2.9 Prognosis 628
37.4 Asperger's Syndrome (ICD-10 F84.5) 628
37.4.1 Historical Development 628
37.4.2 Epidemiology 628
37.4.3 Clinical Features 628
37.4.4 Differences between Childhood Autism and Asperger's Syndrome 628
37.4.5 Comorbidity 628
37.4.6 Treatment 628
37.4.7 Prognosis 628
37.5 Rett's Syndrome (ICD-10 F84.2) 629
37.5.1 Historical Development 629
37.5.2 Epidemiology 629
37.5.3 Inheritance 629
37.5.4 Clinical Features and Course of Illness 629
37.5.5 Treatment 630
37.6 Childhood Disintegrative Disorder (ICD-10 F84.3) 630
37.6.1 Epidemiology 630
37.6.2 Clinical Features 630
37.6.3 Comorbidity 630
37.6.4 Course of Illness 630
37.7 Hyperkinetic Disorder (ICD-10 F90) 630
37.7.1 Attention Deficit and Hyperactivity Disorder (DSM-5 314) 630
37.7.1.1 Terminology 630
37.7.1.2 Epidemiology 630
37.7.1.3 Aetiology 630
37.7.1.4 Genetics 630
37.7.1.5 Neurodevelopment 631
37.7.1.6 Neurochemistry 631
37.7.1.7 Clinical Features 631
37.7.1.8 Rating Scales and Cognitive Assessment 632
37.7.1.9 Further Investigations 632
37.7.1.10 Differential Diagnosis 632
37.7.1.11 Comorbidity 632
37.7.1.12 Treatment 632
37.7.1.13 Psychosocial Treatment 633
37.7.2 Multimodal Treatment Study 634
37.7.2.1 Prognosis 635
37.8 Conduct Disorder (ICD-10 F91.0-F91.2/DSM-5 312) and Oppositional Defiant Disorder (ICD-10 F91.3/DSM-5 313) 635
37.8.1 Epidemiology 635
37.8.2 Aetiology 635
37.8.3 Clinical Features 636
37.8.4 DSM-5 Criteria 636
37.8.5 Sex Differences 638
37.8.6 Differential Diagnosis 638
37.8.7 Comorbidities 638
37.8.8 Management of Conduct Disorder 638
37.8.9 Management of Oppositional Defiant Disorder 639
37.8.10 Prognosis 639

37.9 Elective Mutism (ICD-10 F94.0) 639
37.9.1 Epidemiology 639
37.9.2 Aetiology 639
37.9.3 Diagnosis 639
37.9.4 Clinical Features 639
37.9.5 Management 639
37.9.6 Course and Prognosis 640
37.10 Tic Disorders and Gilles de la Tourette's Syndrome (ICD-10F 95.2; DSM-5 A11) 640
37.10.1 Epidemiology 640
37.10.2 Age of Onset 640
37.10.3 Aetiology 640
37.10.4 Pathophysiology 640
37.10.5 Clinical Features 640
37.10.6 Investigations 641
37.10.7 Differential Diagnosis 641
37.10.8 Comorbidity 641
37.10.9 Management 641
37.10.10 Course of Illness 642
37.11 Pica (ICD-10 F98.3) 642
37.12 Stammering (ICD-10 F98.5) 642
37.13 Cluttering (ICD-10 F98.6) 642
37.14 Communication Disorders (DSM-5) 642
37.15 Nonorganic Enuresis (ICD-10 F98.0; DSM-5 307.6) 642
37.15.1 Definition 642
37.15.2 Epidemiology 642
37.15.3 Clinical Features 642
37.15.4 Aetiology 643
37.15.5 Management 643
37.15.6 Course and Prognosis 643
37.16 Nonorganic Encopresis (ICD-10 F98.1) (DSM 5 307.7) 643
37.16.1 Definition 643
37.16.2 Epidemiology 643
37.16.3 Clinical Features 643
37.16.4 Aetiology 643
37.16.5 Management 643
37.16.6 Course and Prognosis 644
37.17 School Refusal 644
37.17.1 Epidemiology 645
37.17.2 Differences from Truancy 645
37.17.3 Management 645
37.17.4 Course and Prognosis 645
37.17.5 Disorders in Scholastic Skills 646
37.18 Other Psychiatric Disorders in Childhood (0–11 Years) and Adolescence (12–17 Years) 646
37.19 Substance Misuse in Adolescence 646
37.19.1 Type of Substance Misuse 646
37.19.2 Aetiology 647
37.19.3 Smoking 647
37.19.4 Alcohol Abuse in Adolescence 649
37.19.5 Volatile Substances 649

37.19.6 Cannabis 649
37.19.7 Other Substances 649
37.19.8 Treatment 649
37.19.9 Prognosis 649
37.19.10 Legal Aspects of the Child and Adolescent Psychiatry 649
37.20 Physical and Sexual Abuse in Children and Adolescents 653
37.20.1 Epidemiology 653
37.20.2 Assessment 653
37.20.3 Management 657
References 660

Chapter 38 Learning Disability 663

38.1 Classification of Mental Retardation 663
38.1.1 DSM-5 Adopts Similar Classification 663
38.2 Epidemiology of Learning Disability 663
38.3 Aetiology of Learning Disability 663
38.4 Down Syndrome 663
38.4.1 Clinical Case 663
38.4.2 Epidemiology 664
38.4.3 Genetic Mechanism 664
38.4.4 Intelligence 665
38.4.5 Growth 665
38.4.6 Behavioural Features 665
38.4.7 Comorbidity 665
38.5 Learning Disability and Genetic Defects in Sex Chromosomes 665
38.6 Fragile X (Martin-Bell) Syndrome 665
38.6.1 Clinical Case 665
38.6.2 Epidemiology 665
38.6.3 Mode of Inheritance 665
38.6.4 Intelligence 666
38.6.5 Clinical Features 666
38.6.6 Other Clinical Features 666
38.6.7 Psychiatric Features 666
38.6.8 Management 666
38.7 Turner's (XO) Syndrome 666
38.7.1 Epidemiology 666
38.7.2 Mode of Inheritance 666
38.7.3 Clinical Features 666
38.7.4 Intelligence 667
38.7.5 Comorbidity 667
38.7.6 Treatment 667
38.8 Klinefelter's Syndrome (XXY) 667
38.8.1 Case Example 667
38.8.2 Epidemiology 667
38.8.3 Genetic Mechanisms 667
38.8.4 Clinical Features 667
38.8.5 Intelligence 667
38.8.6 Treatment 668
38.9 Other X-Linked Syndromes 668

38.10 XYY Syndrome 668
38.10.1 Epidemiology 668
38.10.2 Mode of Inheritance 668
38.10.3 Clinical Features 668
38.10.4 Intelligence 668
38.11 Learning Disability and Inborn Error of Metabolism 668
38.12 Lesch–Nyhan Syndrome 668
38.12.1 Clinical History 668
38.12.2 Epidemiology 669
38.12.3 Mode of Inheritance 669
38.12.4 Error in Metabolism 669
38.12.5 Clinical Features 669
38.12.6 Behavioural Features 669
38.12.7 Intelligence 669
38.12.8 Medical Comorbidity 669
38.12.9 Treatment 669
38.13 Hurler's Syndrome 669
38.13.1 Case History 669
38.13.2 Epidemiology 669
38.13.3 Mode of Inheritance 669
38.13.4 Error in Metabolism 669
38.13.5 Clinical Features 669
38.13.6 Psychiatric Features 669
38.13.7 Intelligence 669
38.13.8 Causes of Death 669
38.13.9 Treatment 670
38.14 Phenylketonuria 670
38.14.1 Epidemiology 670
38.14.2 Mode of Inheritance 670
38.14.3 Error in Metabolism 670
38.14.4 Clinical Features 670
38.14.5 Behavioural Features 670
38.14.6 Intelligence 670
38.14.7 Screening Test 670
38.14.8 Treatment 670
38.15 Sanfilippo Syndrome 670
38.15.1 Case History 670
38.15.2 Metabolic Problems 670
38.15.3 Intelligence 670
38.15.4 Cause of Death 670
38.15.5 Galactosaemia 670
38.15.6 Epidemiology 670
38.15.7 Mode of Inheritance 670
38.15.8 Metabolic Problems 670
38.15.9 Clinical Features 671
38.15.10 Behavioural Features 671
38.15.11 Intelligence 671
38.16 Metachromatic Leukodystrophy 671
38.16.1 Mode of Inheritance 671
38.16.2 Error of Metabolism 671

38.16.3 Clinical Features ... 671
38.17 Tay–Sachs Disease ... 671
38.17.1 Mode of Inheritance ... 671
38.17.2 Error of Metabolism ... 671
38.17.3 Course of Illness ... 671
38.18 Learning Disability and Neurocutaneous Syndromes ... 671
38.19 Tuberous Sclerosis ... 671
38.19.1 Case History ... 671
38.19.2 Epidemiology ... 671
38.19.3 Mode of Inheritance ... 671
38.19.4 Clinical Features ... 671
38.19.5 Psychiatric Features ... 671
38.19.6 Intelligence ... 672
38.19.7 Comorbidity ... 672
38.20 Neurofibromatosis Type 1 (Von Recklinghausen Disease) ... 672
38.20.1 Epidemiology ... 672
38.20.2 Mode of Inheritance ... 672
38.20.3 Intelligence ... 672
38.20.4 Clinical Features ... 672
38.20.5 Psychiatric Features ... 672
38.21 Learning Disability and Microdeletion Syndromes ... 672
38.22 Prader–Willi Syndrome ... 672
38.22.1 Case History ... 672
38.22.2 Epidemiology ... 673
38.22.3 Mode of Inheritance ... 673
38.22.4 Clinical Features ... 673
38.22.5 Intelligence ... 675
38.22.6 Comorbidity ... 675
38.22.7 Treatment ... 675
38.23 Angelman Syndrome ... 675
38.23.1 Case History ... 675
38.23.2 Epidemiology ... 675
38.23.3 Mode of Inheritance ... 675
38.23.4 Intelligence ... 676
38.23.5 Clinical Features ... 676
38.23.6 Psychiatric Features ... 676
38.24 Williams Syndrome ... 676
38.24.1 Case Scenario ... 676
38.24.2 Epidemiology ... 676
38.24.3 Mode of Inheritance ... 676
38.24.4 Physical Features ... 677
38.24.5 Psychiatric Features ... 677
38.24.6 Intelligence ... 677
38.24.7 Association ... 677
38.25 DiGeorge (Velo–Cardio–Facial) Syndrome ... 677
38.25.1 Epidemiology ... 677
38.25.2 Genetic Defect ... 677
38.25.3 Intelligence ... 677
38.25.4 Clinical Features ... 677
38.25.5 Psychiatric Features ... 677

38.26 Rubinstein—Taybi Syndrome 677
38.26.1 Epidemiology 677
38.26.2 Mode of Inheritance 678
38.26.3 Clinical Features 678
38.26.4 Psychiatric Features 678
38.26.5 Intelligence 678
38.27 Smith–Magenis Syndrome 678
38.27.1 Case History 678
38.27.2 Epidemiology 678
38.27.3 Genetic Defect 678
38.27.4 Clinical Features 678
38.27.5 Psychiatric Features 679
38.27.6 Intelligence 679
38.27.7 Treatment 679
38.28 Cornelia de Lange Syndrome 679
38.28.1 Epidemiology 679
38.28.2 Genetic Mechanism 679
38.28.3 Clinical Features 679
38.28.4 Psychiatric Features 679
38.28.5 Intelligence 679
38.28.6 Comorbidity 679
38.29 Fetal Alcohol Syndrome 679
38.29.1 Epidemiology 679
38.29.2 Pathogenesis 679
38.29.3 Clinical Features 680
38.29.4 Psychiatric Features 680
38.29.5 Intelligence 680
Bibliography 680

Chapter 39 Old-Age Psychiatry 681

39.1 Epidemiology 681
39.2 Physical Processes of Ageing 681
39.2.1 Theories of Ageing 681
39.2.2 Genetic Factors 681
39.2.3 Nongenetic Theories 681
39.2.4 Neurobiology of Ageing 681
39.2.5 Changes in Sleep Architecture 683
39.3 Psychology of Ageing 683
39.3.1 Cognition 683
39.3.1.1 Intellectual Functioning 683
39.3.2 Psychomotor Speed 683
39.3.3 Memory 683
39.3.4 Importance of Loss 684
39.3.5 Personality Changes 684
39.4 Social and Economic Factors in Old Age 684
39.4.1 Attitudes 684
39.4.2 Status 684
39.4.3 Retirement 684
39.4.4 Accommodation 684
39.4.5 Sociocultural Differences 685

39.4.5.1 Social Class....685
39.4.5.2 Ethnicity....685
39.5 Psychopharmacology of Old Age....685
39.5.1 Pharmacokinetics and Pharmacodynamics....685
39.5.1.1 Absorption....685
39.5.1.2 Clearance....685
39.5.1.3 Metabolism....685
39.5.1.4 Distribution....685
39.5.2 Drug Interactions....686
39.5.3 Side Effects....686
39.5.4 Practical Considerations....686
39.6 District Service Provision....686
39.6.1 Principles of Service Provision....686
39.6.2 Needs of Carers....686
39.7 Assessment of a Referral....686
39.7.1 Psychiatric Assessment....686
39.7.1.1 Mental State Examination....687
39.7.2 Investigations....688
39.7.3 Structural Imageing....689
39.7.4 Electroencephalography....690
39.7.4.1 Dementias....690
39.7.4.2 Delirium....690
39.7.5 Psychological Assessment....691
39.7.5.1 Psychometric Testing and Measures of Function....691
39.7.5.2 Experiential Assessment and Analysis of Function....691
39.8 Psychological Reactions to Physical Disease....692
39.8.1 Adjusting to Physical Illness....692
39.8.2 Responses to Physical Illness....692
39.8.3 Psychiatric Consequences of Specific Physical Disorders....692
39.8.3.1 Cerebrovascular Disease....692
39.8.3.2 Sensory Impairment....692
39.9 Mild Cognitive Impairment....692
39.9.1 Epidemiology....692
39.9.2 Pathology....692
39.9.3 Clinical Features....692
39.9.4 Treatment....693
39.10 Dementia in Old Age....693
39.10.1 Risk and Protective Factors for Dementia....694
39.10.2 Alzheimer's Disease....694
39.10.2.1 Aetiology....694
39.10.2.2 Neuropathology....694
39.10.2.3 Clinical Features....695
39.10.2.4 Diagnostic Criteria....695
39.10.2.5 Investigations....696
39.10.2.6 Management....696
39.10.2.7 Management of Behavioural and Psychological Symptoms of Dementia....698
39.10.2.8 Prognosis....698
39.10.3 Vascular Dementia....699
39.10.3.1 Aetiology....699
39.10.3.2 Clinical Features....699
39.10.3.3 Diagnostic Criteria....699

39.10.3.4 Investigation....700
39.10.3.5 Management....700
39.10.3.6 Prognosis....700
39.10.4 Frontotemporal Lobe Dementias....700
39.10.4.1 Epidemiology....700
39.10.4.2 Aetiology and Classification....700
39.10.4.3 Neurochemistry....700
39.10.4.4 Diagnostic Criteria....700
39.10.4.5 Investigations....701
39.10.4.6 Management....701
39.10.4.7 Prognosis....701
39.10.4.8 Diogenes Syndrome....701
39.11 Dementia with Movement Disorders....702
39.11.1 Dementia with Lewy Bodies....702
39.11.1.1 Epidemiology....702
39.11.1.2 Neuropathology....702
39.11.1.3 Neurochemistry....702
39.11.1.4 Clinical Features (McKeith's Criteria)....702
39.11.1.5 Investigations....702
39.11.1.6 Management....703
39.11.2 Parkinson's Disease Dementia....703
39.11.2.1 Aetiology....703
39.11.2.2 Clinical Features....703
39.11.2.3 Management....703
39.11.3 Normal-Pressure Hydrocephalus....704
39.11.3.1 Clinical Features....704
39.11.3.2 Aetiology....704
39.11.3.3 Management....704
39.11.3.4 Prognosis....704
39.11.4 Creutzfeldt–Jakob Disease....704
39.11.4.1 Epidemiology....704
39.11.4.2 Aetiology....704
39.11.4.3 Pathology....705
39.11.4.4 Clinical Features....705
39.11.4.5 Investigations....705
39.11.4.6 Management....705
39.11.4.7 Prognosis....705
39.11.5 Human Immunodeficiency Virus Dementia....705
39.11.5.1 Epidemiology....705
39.11.5.2 Aetiology....705
39.11.5.3 Pathology....705
39.11.5.4 Clinical Features....705
39.11.5.5 Classification....706
39.11.5.6 Differential Diagnosis....706
39.11.5.7 Investigations....706
39.11.5.8 Management and Prognosis....706
39.11.6 Huntington's Disease (Chorea)....706
39.11.6.1 Epidemiology....706
39.11.6.2 Aetiology....706
39.11.6.3 Clinical Features....706

39.11.6.4 Investigation....706
39.11.6.5 Management....707
39.11.6.6 Prognosis....707
39.11.7 General Paralysis of the Insane....707
39.11.7.1 Aetiology....707
39.11.7.2 Clinical Features....707
39.11.7.3 Management and Prognosis....707
39.12 Delirium in Old Age....707
39.12.1 Aetiology....707
39.12.2 Clinical Features....707
39.12.3 Classification....708
39.12.4 Investigation....708
39.12.5 Management....708
39.12.5.1 Nonpharmacological Treatment....708
39.12.5.2 Pharmacological Treatment....708
39.12.6 Prognosis....709
39.13 Depression in Old Age....709
39.13.1 Epidemiology....709
39.13.2 Aetiology....709
39.13.2.1 Genetic Factors....709
39.13.2.2 Neurobiological Factors....709
39.13.2.3 Physical Illness....709
39.13.2.4 Personality....709
39.13.2.5 Environmental Factors....709
39.13.3 Clinical Features....709
39.13.4 Diagnosis....710
39.13.5 Management....710
39.13.6 Prognosis....711
39.14 Mania in Old Age....711
39.14.1 Aetiology....711
39.14.1.1 Genetic Factors....711
39.14.1.2 Organic Factors....711
39.14.2 Clinical Features....712
39.14.3 Management....712
39.14.4 Prognosis....712
39.15 Paraphrenia or Psychosis in Old Age....712
39.15.1 Explanatory Note....712
39.15.2 Epidemiology....712
39.15.3 Aetiology....712
39.15.3.1 Genetic Factors....712
39.15.3.2 Personality....712
39.15.3.3 Sensory Impairment....712
39.15.3.4 Brain Disease....713
39.15.4 Clinical Features....713
39.15.5 Management....713
39.15.5.1 Pharmacological Treatment....713
39.15.5.2 Nonpharmacological Treatment....713
39.15.6 Prognosis....713
39.16 Anxiety in Old Age....713
39.16.1 Epidemiology....713

39.16.1.1 Phobias ... 713
39.16.1.2 Generalized Anxiety Disorder ... 714
39.16.1.3 Panic Disorder ... 714
39.16.2 Aetiology ... 714
39.16.2.1 Environmental Factors ... 714
39.16.2.2 Physical Illness ... 714
39.16.2.3 Comorbidity ... 714
39.16.3 Clinical Features ... 714
39.16.4 Management ... 714
39.17 Further Considerations in Old-Age Psychiatry ... 714
39.17.1 Suicide and Attempted Suicide ... 714
39.17.2 Alcohol and Drug Abuse ... 715
39.17.2.1 Alcohol ... 715
39.17.2.2 Drugs ... 715
39.17.3 Somatization and Somatoform Disorders ... 715
39.17.4 Sexual Activity ... 715
39.17.4.1 Normal Sexual Behaviour in Old Age ... 715
39.17.4.2 Physiological Changes with Ageing ... 715
39.17.4.3 Sexual Problems in Old Age ... 716
39.17.5 Sleep Disorders ... 716
39.17.5.1 Primary Sleep Disorders ... 716
39.17.5.2 Secondary Sleep Disorders ... 716
39.17.6 Bereavement ... 717
39.18 Psychotherapy with Older Adults ... 717
39.18.1 Individual Psychodynamic Therapy ... 717
39.18.2 Adaptations in Therapy ... 717
39.18.3 Transference and Countertransference ... 717
39.18.4 Common Themes ... 717
39.19 Medicolegal Issues in Old-Age Psychiatry ... 717
39.19.1 Elder Abuse ... 717
39.19.2 Management of Financial Affairs ... 718
References ... 720

Chapter 40 Forensic Psychiatry ... 723

40.1 Epidemiology of Offending ... 723
40.1.1 Relationship with Age ... 723
40.1.2 Sex Ratio ... 723
40.2 Juvenile Delinquency ... 723
40.2.1 Aetiology ... 723
40.2.2 Management and prognosis ... 723
40.3 Mentally Abnormal Offenders ... 723
40.3.1 Epidemiology ... 723
40.3.2 Mental Disorders ... 723
40.4 Psychiatric Aspects of Offences ... 723
40.4.1 Shoplifting ... 723
40.4.2 Kleptomania ... 724
40.4.3 Fire Setting ... 725
40.5 Dangerousness ... 725
40.5.1 Multiagency Public Protection Arrangements ... 725

40.6 Risk Assessment 728
40.6.1 Actuarial and Clinical Risk Assessment 728
40.7 Legal Systems in the United Kingdom 731
40.8 Criminal Responsibility in the United Kingdom 731
40.8.1 Definitions 731
40.8.2 Forensic Psychiatric Assessment and Court Reports 731
40.8.3 Classification of Homicide 732
40.8.4 McNaughton Rules 734
40.8.4.1 Diminished Responsibility 734
40.8.5 Automatism 735
40.8.6 Outcome of Sentencing 735
40.9 Civil Aspects 735
40.9.1 Testamentary Capacity 735
40.9.2 Tort 735
40.9.3 Contracts 735
40.9.4 Marriage 735
40.10 Prison Psychiatry 739
References 739

Chapter 41 Preparation for Psychiatric Examinations 741

Preface

The preparation of the third edition of this book has involved a number of major changes. First, we have taken on a new co-author, Roger Ho. Roger has relatively recent experience of preparing for and sitting the examinations of the membership of the Royal College of Psychiatrists and is actively involved in teaching candidates based in Singapore. Second, we have added new chapters and, within existing chapters, we have included new material (including NICE guidelines), updated the DSM-IV-TR criteria to the new DSM-5, and cited more recent references. Finally, we have included many more figures. As with previous editions, we believe the third edition of *Revision Notes in Psychiatry* should prove useful not only for the membership of the Royal College of Psychiatrists but also for similar postgraduate examinations in psychiatry in other parts of the English-speaking world.

Basant K. Puri
Annie Hall
Roger Ho

Authors

Basant K. Puri, MA, PhD, MB, BChir, BSc (Hons) MathSci, DipStat, PG Dip Maths, MMath, FRCPsych, FSB, is based at Hammersmith Hospital and Imperial College London, United Kingdom. He read medicine at St. John's College, University of Cambridge. He also trained in molecular genetics at the MRC MNU, Laboratory of Molecular Biology, Cambridge. He has authored or co-authored more than 40 books, including the second edition of *Drugs in Psychiatry* (Oxford University Press, 2013), the third edition of *Textbook of Psychiatry* with Dr. Ian Treasaden (Churchill Livingstone, 2011) and, with the publisher of the present volume, the third edition of *Textbook of Clinical Neuropsychiatry and Neuroscience Fundamentals* with Professor David Moore (2012).

Annie Hall, BA, MB BCh, MRCPsych is a consultant psychiatrist at South Kensington and Chelsea Mental Health Centre and Chelsea and Westminster Hospital, London, United Kingdom. She read medicine at St Catherines' College, Oxford, and completed her clinical training at the Welsh National School of Medicine. She works in a busy NHS inner-city psychiatric service as a consultant general adult psychiatrist.

Dr. Roger Ho, MBBS, DPM, DCP, Gdip Psychotherapy, MMed (Psych), MRCPsych, FRCPC, is an assistant professor and consultant psychiatrist at the Department of Psychological Medicine, National University of Singapore. He graduated from the University of Hong Kong and received his training in psychiatry from the National University of Singapore. He is a general adult psychiatrist and in charge of the Mood Disorder Clinic, National University Hospital, Singapore. He is a member of the editorial board of *Advances of Psychiatric Treatment*, an academic journal published by the Royal College of Psychiatrists. His research focuses on mood disorders, psychoneuroimmunology, and liaison psychiatry. He is one of the key authors for the revision website, Exam doctor MRCPsych Paper 1 questions (http://examdoctor.co.uk/).

Abbreviations

5-HIAA	5-Hydroxyindoleacetic acid
5-HT	Serotonin
5-HTT	Serotonin transporter
Aβ	Beta-amyloid
AA	Alcoholics anonymous
ACA	Anterior cerebral artery
ACh	Acetylcholine
AChE	Acetylcholinesterase
AChEI	Acetylcholinesterase inhibitor
ACT	Assertive community treatment
ACTH	Adrenocorticotrophic hormone
ADH	Antidiuretic hormone
ADHD	Attention-deficit hyperactivity disorder
ADL	Activities of daily living
AED	Accident and emergency department
AF	Atrial fibrillation
ALDH	Acetaldehyde dehydrogenase
AN	Anorexia nervosa
APA	American Psychiatric Association
ASPD	Antisocial personality disorder
ATP	Adenosine triphosphate
BCh	Butyrylcholinesterase
BDD	Body dysmorphic disorder
BDNF	Brain-derived neurotrophic factor
BMI	Body mass index
BN	Bulimia nervosa
BNF	British National Formulary
BPSD	Behavioural and psychological symptoms in dementia
BZD	Benzodiazepine
CADASIL	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CAMCOG	Cambridge Cognitive Examination
CAMDEX	Cambridge Examination for Mental Disorder of the Elderly
CAMHS	Child and Adolescent Mental Health Services
cAMP	Cyclic adenosine monophosphate
CASC	Clinical Assessment of Skills & Competencies
CAT	Cognitive analytic therapy
CBF	Cerebral blood flow
CBT	Cognitive behavioural therapy
CBT-Gp	Group-based CBT
CBT-Mb	Mindfulness-based CBT
CBT-Tf	Trauma-focused CBT
CCBT	Computerized CBT
CCK	Cholecystokinin
CD	Cluster of differentiation
ChAT	Choline acetyltransferase
CJD	Creutzfeldt–Jakob disease
CK	Creatinine kinase
CMHT	Community mental health team
CMV	Cytomegalovirus
CN	Cranial nerve
CNS	Central nervous system
COMT	Catechol-O-methyl transferase
CPA	Care programme approach
CPMS	Clozaril Patient Management System
CPN	Community psychiatric nurse
CR	Chronic release
CRF	Chronic renal failure
CRP	C-reactive protein
CSF	Cerebrospinal fluid
CT	Computed tomography
CVA	Cerebrovascular accident
CVS	Cardiovascular system
DBT	Dialectical behaviour therapy
DDX	Differential diagnosis
DLPFC	Dorsolateral prefrontal cortex
DM	Diabetes mellitus
DSH	Deliberate self-harm
DST	Dexamethasone suppression test
DT	Delirium tremens
DVLA	Drive and Vehicle Licensing Agency (United Kingdom)
DZ	Dizygotic
ECG	Electrocardiogram
ECT	Electroconvulsive therapy
ED	Erectile dysfunction
EE	Expressed emotion
EEG	Electroencephalogram
EPI	Eysenck Personality Inventory
EPSE	Extrapyramidal side effects
ERP	Exposure and response prevention
ESR	Erythrocyte sedimentation rate

FAS	Foetal alcohol syndrome
FBC	Full blood count
FRS	First-rank symptoms
FSH	Follicle-stimulating hormone
FTD	Fronto-temporal dementia
GA	General anaesthesia
GABA	γ-Aminobutyric acid
GAD	Generalized anxiety disorder
GAF	Global assessment of functioning
GDS	Geriatric Depression Scale
GFR	Glomerular filtration rate
GH	Growth hormone
GI/GIT	Gastrointestinal/gastrointestinal tract
GMC	General Medical Council
GP	General practitioner
HCG	Human chorionic gonadotropin
HMSN	Hereditary motor and sensory neuropathies
HPA	Hypothalamic–pituitary–adrenal
HSV	Herpes simplex virus
HVA	Homovanillic acid
HVS	Hyperventilation syndrome
IBS	Irritable bowel syndrome
ICP	Intracranial pressure
IDDM	Insulin-dependent diabetes mellitus
IHD	Ischaemic heart disease
IM	Intramuscular
IMR	Inmate record
IPT	Interpersonal therapy
IUGR	Intrauterine growth retardation
IV	Intravenous
K	Potassium
K-SADS-PL	Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version
LBD	Lewy body dementia
LC	Locus coeruleus
LD	Learning disability
LFT	Liver function test
LH	Luteinizing hormone
LMBBS	Laurence–Moon–Biedl syndrome
LMNL	Lower motor neurone lesion
LOC	Loss of consciousness
LOCF	Last observation carried forward
LP	Lumbar puncture
LTM	Long-term memory
MAOI	Monoamine oxidase inhibitor
MCA	Middle cerebral artery
MCQ	Multiple-choice question
MCI	Mild cognitive impairment
M:F	Male-to-female ratio
MDMA	Methylenedioxymethamphetamine
MDT	Multidisciplinary team
Mg	Magnesium
MHA	Mental Health Act
MI	Myocardial infarction
MLF	Medial longitudinal fasciculus
MMR	Measles, mumps, and rubella
MMSE	Mini-mental state examination
MRCPsych	Member of the Royal College of Psychiatrists
MRI	Magnetic resonance imaging
MS	Multiple sclerosis
MSE	Mental state examination
MSU	Midstream urine
MSW	Medical social worker
^{99}mTc-HMPAO	Tc99m hexamethylpropyleneamine oxime
MVP	Mitral valve prolapse
MZ	Monozygotic
NA	Noradrenaline
NAI	Nonaccidental injury
NART	National Adult Reading Test
NAS	Neonate abstinence syndrome
NF	Neurofibromatosis
NFT	Neurofibrillary tangle
NHS	National Health Service (United Kingdom)
NICE	National Institute for Health and Care Excellence (United Kingdom)
NMDA	N-methyl-D-aspartate
nocte	Every night
NPH	Normal pressure hydrocephalus
NRT	Nicotine replacement therapy
NSAID	Nonsteroidal anti-inflammatory drug
OCD	Obsessive–compulsive disorder
OCPD	Obsessive–compulsive personality disorder
ODD	Oppositional defiant disorder
OM	Every morning
OT	Occupational therapist
PANDAS	Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
PANSS	Positive and Negative Syndrome Scale
PCA	Posterior cerebral artery
PCOS	Polycystic ovary syndrome
PCP	Phencyclidine
PCS	Postconcussion syndrome
PDD	Pervasive development disorder